speakers 4th annual cancer biopartnering & investment · pdf file ·...

SUPPORTING ORGANISATIONSORGANISERS

PRESENTING COMPANIES

WELCOM

ESPEAKERS

4th Annual

Cancer BioPartnering & Investment Forum Focusing on Advances in Immuno-Oncology

www.sachsforum.com

24th February 2016New York Academy of Sciences • USA

Conference Guide

4T

H A

NN

UA

L C

AN

CE

R B

IOP

AR

TN

ER

ING

& I

NV

ES

TM

EN

T F

OR

UM



WELCOM

ESPEAKERS

4th ANNUAL

Cancer BioPartnering & Investment Forum

4th AnnualCancer BioPartnering & Investment Forum

Request for PresentationsPlease use the agenda to mark off presentations that you are interested in and email your request to [email protected] after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference.

Sachs Associates are delighted to welcome you to the:

General Information• The registration desk is open from 8.00am on 24th February although you are welcome to

join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

• One-to-one meetings Please bring with you a copy of your diary. Should you have any queries about your schedule, the laptop situated by the meeting tables is available for your assistance.

Sachs Associates, building upon it’s many years of expertise in organizing premier

partnering and investor meetings in Europe and the United States, is proud to

welcome you to the 4th Annual Cancer BioPartnering & Investment Forum being held on 24th February 2016 at the New York Academy of Sciences.

This forum is designed to bring together thought leaders from cancer research

institutes, patient advocacy groups, pharma and biotech to facilitate partnering and

funding/investment.

Sachs Associates would like to thank our sponsors and partners who have helped

make this event possible.

4th Annual

Cancer BioPartnering & Investment ForumFocusing on Advances in Immuno-Oncology 24th February 2016 • New York Academy of Sciences • USA



WELCOM

ESPEAKERS

4th ANNUAL



Events Diary

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Silvia Kar on [email protected]

9th Annual European Life Science CEO Forum & ExhibitionPartnering & Investing in Biotech & Pharma Industry15th – 16th March 2016 • Hilton Zurich Airport Hotel • SwitzerlandThis event will be highly transactional, bringing together an exciting cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders. We expect around 350 delegates and 80 presenting companies. Event’s networking will be powered by online One-2-One meeting system and dedicated meeting facilities to make the event more transactional and productive.

2nd Annual Immuno-Oncology: BD&L and Investment Forum 3rd June 2016 • Hyatt Chicago Magnificent Mile • USA

The 2nd Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding & investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online One-2-One meeting system with dedicated meeting facilities to make the event more transactional.

4th AnnualMedTech & Digital Health Forum for Technology & Healthcare Innovation26th September 2016 • Congress Center Basel • SwitzerlandThe programme is designed to highlight the latest industry developments and showcase emerging and innovative technology companies seeking finance and partnerships. The delegates are comprised of Healthcare, MedTech, Healthcare IT, and Digital Health companies as well as consultants, bankers and corporate & financial investors. We expect over 200 delegates and 25 presenting companies plus demos.

16th AnnualBiotech in Europe Forum For Global Partnering & Investment27th – 28th September 2016 • Congress Center Basel • SwitzerlandThe forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s bio industry, this event will once again be covered by our regular media partners. We expect over 600 delegates and 100 presenting companies.



WELCOM

ESPEAKERS

Speakers

4th ANNUAL



Anne Altmeyer, VP Business Development Negotiations, Baxalta

Anne has about 20 years of experience in the Pharmaceutical Industry working in positions of increasing responsibilities in Research, Development, and Business Development.

Since September 2015, Anne Altmeyer is a Vice President Business Development & Licensing at Baxalta. In this capacity, Anne focuses on global transactions for Baxalta’s three businesses: Oncology, Hematology, and Immunology. From 2004 to August 2015, Anne worked at Novartis. Most recently, she was Vice President, Business Development & Licensing in the Oncology Business Unit. In this capacity, her responsibilities were to in-license or acquire Oncology assets. She also oversaw the Companion Diagnostics Business Development group and managed several alliances. Before joining Business Development, Anne worked as a Project Leader in the Novartis’ Project Management Group. There, she led multidisciplinary Project Teams through the generation and implementation of strategies for several compounds in development and on the market. Before joining Novartis, Anne worked as a Project Manager in various Therapeutic Areas at Merck & Co.

Anne received her Ph.D. in Molecular Immunology from Strasbourg University, France. She then performed a postdoctoral fellowship at New York University School of Medicine, New York, USA, and subsequently became a Research Associate at Cornell University Medical College, New York, USA. In addition to her scientific training, Anne also received a MBA and a MPH from the University of Medicine and Dentistry of New Jersey/Rutgers University, USA.

Bard Geesaman, Managing Director, MPM Capital

Bard J. Geesaman, M.D., Ph.D., has been with MPM and associated portfolio companies since 2002. He has broad experience investing, operating and facilitating business development globally, including in Japan, China and Israel. Prior to joining MPM, Bard founded Catalyst Medical Solutions, a medical documentation and billing eHealth company in Boston where he served as the Chief Technology Officer through the company’s acquisition. After Catalyst, Bard joined Centagenetix, an MPM-founded company exploring the genetics of successful aging.

In 2006, Bard joined MPM as a Venture Partner with a major focus on founding Solasia Pharmaceuticals, based in Tokyo, Japan. Bard is also the co-founder and a board member of MPM healthcare IT startup TriNetX (big data analytics for clinical trials). Bard is passionate about innovation in health care, and in 2008 took a two year sabbatical from MPM to do non-profit work in Los Angeles at the X-Prize Foundation, where he worked on alternative models for motivating life sciences innovation.

He received a B.S. in neuroscience from U.C. Berkeley followed by concurrent degrees from Harvard Medical School and M.I.T., with his Ph.D. work focused on systems and computational neurobiology. Bard finished his medical training by completing a three-year medical residency at Massachusetts General Hospital.

André Choulika, Chairman and CEO, Cellectis

André Choulika, Ph.D., is one of the founders of Cellectis and has been Chairman of the Board and Chief Executive Officer since 2000. He has also been President of Calyxt (previously Cellectis plant sciences) since August 2010.

From 1997 to 1999, Dr Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was a pioneer in the analysis and use of meganucleases to modify complex genomes. He has also served on the boards of directors of several biotechnology companies.

After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. Dr Choulika also has management training from the HEC (Challenge +).



WELCOM

ESPEAKERS

Speakers

4th ANNUAL



Brad Loncar, Chief Executive Officer, Loncar Investment, LLC

Brad Loncar is an independent biotechnology investor and Chief Executive Officer of Loncar Investments, LLC. In 2015, the Loncar Cancer Immunotherapy ETF (CNCR) launched on the NASDAQ stock market. Mr. Loncar incorporates his extensive research into biotech companies and technologies to develop indexes focused on precise investment opportunities. He previously worked in the financial services industry at Franklin Templeton Investments, and was appointed to serve in a Senior Adviser role at the U.S. Department of the Treasury.

Boris Peaker, Managing Director, Biotechnology Equity Research, Cowen Group

Boris Peaker is a managing director and senior research analyst covering emerging growth biotechnology companies. Prior to re-joining Cowen in 2014, Dr. Peaker was a senior analyst at Oppenheimer & Co. and Rodman & Renshaw, covering large-, mid-, and small-cap biotechnology stocks. Dr. Peaker holds a BS in physics and chemistry from Stony Brook University and a Ph.D. in biophysics from Stanford University. He is a CFA charterholder.

Bibhash Mukhopadhyay, Principal, New Enterprise Associates

Bibhash is a Principal at New Enterprise Associates (NEA), where he focuses on investing in emerging therapeutics and device companies, assisting them grow and create value. Previously, he was at AstraZeneca-MedImmune as an Associate Director of Business Development, with focus on the immune-oncology and immunology. He started his career at Johnson and Johnson. Prior to that, he conducted doctoral research work on retinal diseases and consulted for venture funds and start-ups.

Beth Jacobs, Managing Partner, Excellentia Global Partners

Beth Jacobs is the Managing Partner of Excellentia Global Partners based in New York. EGP serves US, European and Asian-based clients on a range of engagements, raising capital, global strategy and growth through both organic and M&A approaches. She is active in scientific and social service not-for-profits, serving on the boards of The New York Academy of Sciences, as Governor and Executive Committee member, EF Foundation, Cambridge, Massachusetts, Harvard Kennedy School Womens Leadership Board, William J. von Liebig Foundation for Medical Research, Susan G. Komen Foundation – Global Ambassador, and as a special advisor to the Board of Positive Exposure.

Since 1982, Beth has built, managed and executed with some of the largest International Divisions in global investment banking, including Prudential Bache, Morgan Stanley, Shearson Lehman and ING Barings – Furman Selz. She held the position of Senior Vice President for Laureate Education (private), working across all business units in a corporate development role with a distinct focus on identifying and executing on opportunities in China. Beth received an MBA in international finance from American University in Washington, DC in conjunction with the School of Foreign Service, BA, cum laude, from Boston College and studied at Centre d’Etudes Internationale, Geneva, Switzerland diplomatic program.



WELCOM

ESPEAKERS

Speakers

4th ANNUAL



Ferran Prat, VP, Strategic Industry Ventures, MD Anderson Cancer Center

Ferran Prat, Vice President of Strategic Industry Ventures MD Anderson Cancer CenterPrat helps the faculty and researchers at MD Anderson develop collaborative opportunities with pharmaceutical, biotech, diagnostics, imaging, laboratory medicine and other industry partners. He is responsible for establishing a direct line of contact with pharmaceutical companies to understand their needs in terms of pre-clinical and Phase 1 activities, and internally convey them so that the researchers and clinicians at MD Anderson can follow-up and establish personal relationships with such companies.

Prior to joining MD Anderson he worked at Alere Inc., an international firm dedicated to developing health management services and solutions, including diagnostic tools and tests. At Alere, Ferran led a business turnaround and integrated three businesses in São Paulo and Belo Horizonte, Brazil. He also served as the head of the Oncology and Women’s Health Divisions in San Diego, where he was responsible for all pre-commercialization activities and post-launch product management.

Prior to Alere, Ferran held a number of industry and academic positions, including vice president for licensing at Biosite Inc., management consultant at McKinsey & Co., engineer at Chromogenia-Units and researcher at the University of California – Los Angeles. In these roles, he in-licensed and out-licensed new technologies, led and executed strategic plans, coordinated intellectual property agreements among private and public sector entities, and conducted basic science research that led to multiple peer-reviewed articles.

Prat has a Ph.D. in organic chemistry from the University of California – Los Angeles and a J.D. from the University of San Diego School of Law.

Dennis Purcell, Founder and Senior Advisor, Aisling Capital, LLC

During his tenure, Dennis has been directly involved with over two hundred completed transactions and supervised over $15 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. Dennis is a frequent commentator on the industry and has been honored in various publications as a top contributor to the Life Sciences industry. He sits on numerous private and public healthcare company boards and is actively involved with many of the industry’s professional organizations, such as BIO, the Life Sciences Foundation, the NYC Investment Fund and NYU’s office of Therapeutics Alliance. Dennis received his M.B.A. from Harvard University and his B.S. in Accounting from the University of Delaware.

Daniel Teper, CEO, Immune Pharmaceuticals, Inc.

Dr. Daniel Teper is the founder and CEO of IMMUNE Pharmaceuticals. Dr. Teper was the Managing Director for North America at Bionest Partners, a global Strategy Consulting firm advising pharmaceutical and public biotechnology companies and previously a New York based Partner at ISO Healthcare Consulting (now part of Monitor Group). Daniel started his career at Sandoz (now Novartis) Global Headquarters in Basel and then in the United States where he had growing responsibilities in sales, marketing and new product development. He held senior executive positions in Europe, first at GSK as Head of Commercial Operations for Glaxo France and then as President and Chief Operating Officer of Laboratoires Delagrange through the acquisition by Synthelabo (now part of Sanofi). He then became President at Global EURO RSCG Healthcare Worldwide, a leading marketing and communication group, where he helpedlaunch multiple industry blockbusters. Daniel was a cofounder of Novagali (NYSE Euronext: NOVA), which was recently acquired by Japan’s Santen. Dr. Teper holds a Doctor of Pharmacydegree (PharmD) from Paris XI University and an MBA from INSEAD.

Chris Marai, Managing Director, Biotechnology Equity Research, Oppenheimer & Co. Inc.

Christopher Marai Ph.D. is a Managing Director and Senior Analyst covering the Biotechnology sector at Oppenheimer and Co. Inc. Christopher was most recently at Wedbush Securities PacGrow Life Sciences as a Vice President and Senior Analyst covering Biotechnology and Biopharmaceuticals with a particular focus on rare diseases, oncology and advanced antibody technologies. He started his Wall Street career at Morgan Stanley in 2006 and previously co-founded a computationally focused rational drug design consulting firm. Christopher holds a Ph.D. in Biochemistry and Structural Biology from Stony Brook University and a B.Sc. in Chemistry from Trinity College/University of Toronto.



WELCOM

ESPEAKERS

Speakers

4th ANNUAL



James Mulé, Associate Center Director for Translational Science, Moffitt Cancer Center

Dr. Mulé is the Associate Center Director for Translational Science, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and Director of Cell-based Therapies at the Moffitt Cancer Center, Tampa, Florida.

Dr. Mulé, who was recently designated a “Master of Immunology” by the American Association for Cancer Research, is recognized for his research and clinical trial contributions to cancer immunotherapy, particularly in solid tumors. His clinical research group is involved in developing and validating genomic signatures of immunotherapy response, as well as vaccine strategies (e.g., with dendritic cells) and other approaches (e.g., with adoptive T cells) to recognize and destroy tumors. The translational work in these areas has helped to develop new treatments for advanced cancer patients.

Dr. Mulé serves on Advisory Boards of numerous biotechnology and pharma companies (e.g., OncoPep, Lion Biotech, Oxis, Vault Nano, Celgene, among others). He remains a long-standing special government employee to the FDA (CBER) and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. He currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific Counselors (BSC-A). Dr. Mulé also serves on the Editorial Boards of several peer-reviewed journals, including Scientific Reports (nature.com), Journal of Immunotherapy, and Cancer Immunology Research (AACR). He has published nearly 200 articles in the areas of cancer vaccines and adoptive immunotherapy, and is a continuously funded investigator for nearly 25 years.

Dr. Mulé received a special individual Ph.D. (IPh.D.) degree in Tumor Immunology from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington. He then received his formal post-graduate training at the Surgery Branch, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland, where he became a Senior Investigator with tenure. Dr. Mulé moved to Palo Alto, CA, where he helped to launch and scientifically direct two biotechnology companies. He then moved to Ann Arbor, Michigan to become the Director of the Tumor Immunology and Immunotherapy Program at the University of Michigan Comprehensive Cancer Center, the Maude T. Lane Endowed Professor of Surgery with tenure, Department of Surgery, and Professor in the Department of Internal Medicine.

Gregory Frost, Managing Director, F1BioVentures

Howard Fingert, Senior Medical Director, Internal and External Innovation for Oncology, Takeda Pharmaceuticals

Dr. Fingert is a Senior Medical Director, Takeda Oncology in Cambridge, MA. Board certified in Oncology and Hematology, he has 20+ years Industry experience in Clinical R&D, Regulatory Affairs, Business Development. He now serves as clinical lead for External Innovation, managing R&D partnerships with academic centers and biotech companies in US, EU, Japan. In addition to Industry roles managing Early- and Late- stage product development at Takeda, Pfizer and other companies, he supported successful registration of numerous I/O, biologic, and drug products through his recent 3-year term as Industry Representative to FDA Oncology Drugs Advisory Committee (ODAC). Prior to Industry, he was faculty at Mass General Hospital and Dana Farber Cancer Institute, and published translational research, cancer pharmacology, and Phases 1-3 clinical trials.



WELCOM

ESPEAKERS

Speakers

4th ANNUAL



Jeffrey Bacha, Chairman and Chief Executive Officer, DelMar Pharmaceuticals

Jeffrey Bacha has been the Chief Executive Officer, President and a director of DelMar Pharmaceuticals since 2013. Mr. Bacha is a seasoned executive leader with nearly twenty years of life sciences experience in the areas of operations, strategy and finance. His background includes successful public and private company building from both a start-up and turn around perspective; establishing and leading thriving management and technical teams; and raising capital in both the public and private markets. Previously Mr. Bacha was Executive Vice President Corporate Affairs and Chief Operating Officer at Clera, Inc. and held various positions at Urigen Holdings Inc. and XBiotech, Inc. He also served as President & CEO of Inimex Pharmaceuticals, a venture-capital funded drug discovery and development company and is a former Senior Manager and Director of KPMG Health Ventures. Mr. Bacha holds an MBA from the Goizueta Business School at Emory University and a degree in BioPhysics from the University of California, San Diego.

Joseph Brantuk, Vice President, Global Corporate Client Group, Nasdaq OMX

Joseph Brantuk is Vice President of the Global Corporate Client Group at NASDAQ OMX (NASDAQ: NDAQ), the world’s largest exchange company. In this role, Mr. Brantuk manages NASDAQ’s new listings efforts in domestic listings across all sectors. He brings over ten years of experience within the exchange field, to bear on his work in guiding companies and their legal financial advisors on the process of listing on the U.S.’s largest electronic market.

His focus on working with early stage companies to maximize the financing and visibility opportunities that can be provided by public capital markets means he also works very closely with venture capital, private equity and investment firms to educate them on the liquidity options NASDAQ can provide. His background is in investment research and capital markets. Mr. Brantuk works with companies by providing value-added consultative services. He analyzes and interprets market transaction and performance data, and educates companies on the benefits of NASDAQ.

Mr. Brantuk attended Trinity College in Hartford, CT and resides in Garden City, NY with his wife and four children.

Jeff Bockman, Vice President, Defined Health

Jeff leads the Oncology and Virology Practices at Defined Health. Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He has directed hundreds of in-depth licensing opportunity and valuation assessments during his tenure at DH. He often speaks at conferences on scientific and commercial issues in cancer, biologics and personalized medicine.

Before joining Defined Health, Jeff was a Senior Research Scientist and Research Project Leader in the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories; and an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients: Dr. Sidney Altman on ribozymes, and Dr. Stanley Prusiner on prions, and holds four patents in the use of ribozymes..

He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University.

Jeff is a member of the Licensing Executives Society (LES), the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the American Society of Gene and Cell Therapy (ASGCT).



WELCOM

ESPEAKERS

Speakers

4th ANNUAL



Laurent Audoly, Managing Partner – Head of R&D, Pierre Fabre Fund For Innovation

Dr. Laurent Audoly is Senior Vice President and heads Research and Development at Fabre Pharmaceuticals for both novel medicines and consumer healthcare products. Laurent is also Managing Partner and Founder of the Pierre Fabre Fund for Innovation. In addition, Laurent is president of the Orphan Diseases and the Medical Devices units within Pierre Fabre.

Prior to this role, Laurent was Chief Scientific Officer in biotech focused on next generation therapeutic proteins where he led the growth of the pipeline from no drug candidates prior to his arrival to a high value pipeline and multiple strategic partnerships with big pharma ultimately leading to a successful exit.

Laurent has held positions of increasing leadership responsibilities in the pharmaceutical industry (Pfizer, Merck, MedImmune) contributing to the identification of new projects and the development of five approved drugs in inflammation, dermatology, cardiovascular diseases, and oncology as well as leading large teams across the pharma value chain.

Throughout his career, he has championed high impact collaborations and established a world-wide network of academic and company-based partnerships. Many of these collaborations have resulted in drug development projects. Laurent is focused on strategic and business growth and has also established strong connections with internal and external commercial and manufacturing organizations. He studied medicine and chemistry for his Bachelor’s degree and graduated with a Ph.D. in Pharmacology from Vanderbilt University. Laurent was awarded a fellowship from the American Heart Association during his post-doctoral training at Duke University. Laurent has maintained strong ties with the academic world as an Associate Professor (Adj) at Duke NUS Graduate Medical School. He has also served on NIH study sections, given seminars at universities across the world, and published > 70 papers and patents. He is on the board and an advisor for multiple healthcare organizations across the world aimed at improving healthcare and accelerating the discovery and advancement of novel therapies for patients and their families.

Matthew Roden, UBS Equity Research, UBS

Matthew Roden, PhD, is an Executive Director and Senior Analyst at UBS, leading coverage of US biotechnology stocks. Matt joined UBS in 2010 from Bank of America Merrill Lynch, where he was a Vice President and Senior Analyst covering US biotechnology. Previously he spent 4 years at J.P. Morgan, where he was the Vice President on the Institutional Investor #2-ranked biotech franchise. Matt’s equity research career started at Credit Suisse First Boston as an associate analyst covering biotechnology. Matt holds a PhD in Microbiology and Immunology from the Albert Einstein College of Medicine, and was awarded a Fellowship at the National Cancer Institute, where he studied immuno-oncology (preceptor: Dr. Steven Rosenberg). Matt also holds a M.S. degree from Georgetown University and a B.S. degree from George Mason University.

Dr. Laurence Cooper, CEO, ZIOPHARM Oncology, Inc. and Visiting Scientist, Pediatrics – Research, MD Anderson Cancer Center

Laurence Cooper M.D., Ph.D., serves as Chief Executive Officer of ZIOPHARM Oncology and maintains a position as a Visiting Scientist at MD Anderson Cancer Center (MDACC). Dr. Cooper joined ZIOPHARM in 2015, following the licensing agreement between Intrexon and ZIOPHARM with MDACC. This agreement, the largest in the center’s history, strengthens ZIOPHARM’s novel gene expression, control and cell technologies to deliver safer, more effective and scalable cell-based therapies for the treatment of cancer, including CAR T and other non-viral and viral gene transfer methods. Prior to this appointment, Dr. Cooper was a tenured Professor at The University of Texas with joint appointments in the Division of Pediatrics and Department of Immunology. He joined MDACC in 2006 as Section Chief of Cell Therapy at the Children’s Cancer Hospital at MDACC where he cared for children undergoing bone marrow transplantation and led scientific efforts to develop new treatment approaches that pair genetic engineering with immunotherapies. Dr. Cooper has coauthored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under INDs infusing T cells and NK cells. He is undertaking the first protocols using a new approach to gene therapy of genetically modified T cells based upon the Sleeping Beauty transposon/transposon system and has helped develop clinical-grade artificial antigen presenting cells for numerically expanding and activating immune cells.



WELCOM

ESPEAKERS

Speakers

4th ANNUAL



Michael Woo, Director, Search & Evaluation ImmunoOncology, External Innovation, Global Research & Development , EMD Serono, Inc.

Dr. Michael Woo heads Search and Evaluation in Immuno-Oncology at EMD Serono. Michael has broad experiences in business development and drug development. Prior to joining EMD Serono, Michael served in areas of increasing responsibility in Business Development & Licensing at Novartis Oncology, leading Due Diligence and actively participating in Search and Evaluation for oncology therapeutics. Before joining Novartis, Michael was leading Due Diligence in the areas of Oncology, Immunology, Infectious Diseases, and Neuroscience in Roche Partnering. Michael has been an active member of deal teams that have completed deals and strategic partnerships in Oncology and Immuno-Oncology. Michael has also served on global program teams responsible for the development of small molecules and biologics in Oncology from Phase 1 through Regulatory filing at Bristol-Myers Squibb and at Roche.

Michael received a B.Sc.Phm. from the University of Toronto, an M.S.C.I. from Vanderbilt University, an M.B.A from New York University Stern School of Business, and a Doctor of Pharmacy from Wayne State University.

Michael is a member of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).

Michael Aberman, SVP, Strategy and Investor Relations, Regeneron Pharmaceuticals, Inc.

Michael Aberman, MD joined Regeneron in 2010 as Vice President, Strategy and Investor Relations. Prior to joining Regeneron, Dr. Aberman was a Wall Street research analyst covering the biotechnology industry. Most recently, he was Director and Senior Biotechnology Analyst at Credit Suisse and prior to that, Vice President and Biotech Analyst at Morgan Stanley. Before moving to Wall Street, Dr. Aberman was Director of Business Development at Antigenics, Inc., an oncology-focused biotechnology company. Dr. Aberman received his medical degree from the University of Toronto, completed residency training in Internal Medicine at New York Presbyterian Hospital/Weill Cornell Medical Center, and received an M.B.A. from The Wharton School of Business.

Michael Khan, Chief Medical Officer, Silence Therapeutics

Mike completed his clinical training at Guy’s and King’s College London in 1985. Subsequently, awarded a doctorate in Developmental Neurobiology from University College London, where he also completed specialist training in Internal Medicine, Endocrinology and Diabetes. Elected a Fellow of The Royal College of Physicians in 2002 and the Association of Physicians of Great Britain and Ireland in 2004, with over 17 years wide-ranging clinical experience in the NHS as a Consultant Physician in General Internal Medicine. Director of the largest screening service for Coronary Disease Prevention and Genetically-determined Dyslipidaemias in England. Highly cited research in translational medicine and cancer biology and author of 5 books, including two editions of the Molecular Biology of Cancer- a bridge from bench to bedside. Former Head of Molecular Medicine and Associate Professor of Medicine at the University of Warwick, with responsibility for strategic development of medical research and played a major role in helping to establish both Warwick Medical School and Warwick Systems Biology. Expert advisor to the European Commission and the National Institute of Clinical Excellence (NICE), including setting the recent National Clinical Guidelines for Lipid-lowering Drugs and Coronary prevention (CG181). For the last four years has been an Executive Director and CMO of Silence Therapeutics PLC.

Maurice Zauderer, Founder, President & CEO, Vaccinex, Inc.

Maurice Zauderer, Ph.D. has served as President and Chief Executive Officer of Vaccinex, Inc. since its inception in April 2001. Prior to founding the company, Dr. Zauderer held a senior faculty position at the University of Rochester Cancer Center and on the Biological Sciences faculty at Columbia University. Dr. Zauderer received a B.S. in Physics from Yeshiva University and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology. He has served as a scientific advisor at the National Multiple Sclerosis Society (1992-1997), on various study sections and review committees at the National Institutes of Health and the National Science Foundation, and as Associate Editor of the Journal of Immunology (1987-1989 and 1994-1999).



WELCOM

ESPEAKERS

Speakers

4th ANNUAL



Niels Emmerich, Senior Director, Head Search and Evaluation Oncology, AbbVie, Inc.

Niels joined the pharmaceutical division of Abbott (now AbbVie) in 2011 and currently serves as Senior Director, Global Head of Search & Evaluation, Oncology. Prior to joining AbbVie, Niels was CEO of BioPheresis, an immuno-oncology-focused medical device company. Before joining BioPheresis Niels was co-founder and COO immatics biotechnologies, a biotech company focused on identification of T-cell antigens. Prior to that Niels was an associate with McKinsey & Company. Niels received a Ph.D in Immunology and M.Sc. in Biology from University of Tuebingen.

Niranjan Sardesai, COO, Inovio Pharmaceuticals, Inc.

Niranjan Y. Sardesai was appointed Chief Operating Officer of Inovio in January 2012. He served as the Company’s Senior Vice President of Research and Development following the June 2009 merger with VGX Pharmaceuticals, at which company he held the same position. Dr. Sardesai joined VGX Pharmaceuticals in 2006 where he helped formulate the company’s product development and growth strategies and reorganized the company into a DNA vaccine and immunotherapies company. Across VGX and Inovio, Dr. Sardesai drove multiple M&A and licensing transactions to consolidate key technologies, establish the corporate footprint, and develop its immunotherapies platform and product pipeline. He led the strategic out-licensing of Inovio’s pipeline products to secure major licensing deals with big pharma companies. He has raised over $130 MM in non-dilutive grants and contract funding from government and non-government organizations and served as Principal Investigator on multi-institutional programs developing Inovio’s oncology and infectious disease products. Under his leadership, Inovio’s development stage products have been recognized by several pharmaceutical industry awards for innovation and the potential to address significant unmet needs.

Dr. Sardesai was previously the founder and President of NVision Consulting Inc., a firm providing strategic counsel to entrepreneurial life sciences companies. He served as Director of Research and Development at Fujirebio Diagnostics, Inc., where he oversaw the expansion of the company’s oncology portfolio. Products developed under his leadership include groundbreaking new tests for mesothelioma (MESOMARK™), bladder cancer and a multi-marker test for ovarian cancer.

Dr. Sardesai received a Ph.D. in Chemistry from the California Institute of Technology and an MBA (entrepreneurship and finance) from the Wharton School of the University of Pennsylvania, where he was the recipient of the Shils-Zeidman Award in Entrepreneurship. He was awarded fellowships at the Scripps Research Institute and the Massachusetts Institute of Technology (MIT). Dr. Sardesai received his Bachelor and Master of Science degrees in Chemistry from the Indian Institute of Technology, Bombay. He has authored over 100+ peer-reviewed manuscripts and book chapters with particular contributions in vaccines and immunotherapies, oncology, and medical devices; presented at over 120+ invited lectures and presentations, and filed several patents. Dr. Sardesai was recently recognized by Pharmavoice magazine as one of the top 100 most influential and inspirational leaders from across the life sciences and healthcare industry (2015).

Mohamed Ragab, VP Oncology, S&E, BD, Bristol-Myers Squibb Company

Mohamed H. Ragab, MD is the Global Head, Search and Evaluation, Immuno-Oncology/ Oncology in the Business Development group at BMS. His day to day responsibilities include conducting initial evaluation and detailed assessment of licensing and acquisition opportunities in the oncology/immune-oncology therapeutic area.

Mohamed joined Search and Evaluation at BMS in 2013 from his previous position as Global Partnering Head, Oncology, at Hoffman La Roche, Inc. Prior to joining BMS, Mohamed held positions within Oncology/Business Development at Pfizer, Ortho Biotech, Schering Plough and Egyptian National Cancer Institute. Additionally, Mohamed represents BMS on the board of Bio NJ.

Mohamed has a Bachelor of Medicine and Surgery degree and a M.Sc. in Radiation Oncology from Cairo University School of Medicine.



WELCOM

ESPEAKERS

Speakers

4th ANNUAL



Pedro Lichtinger, Chief Executive Officer, Asterias Biotherapeutics, Inc.

Pedro Lichtinger became our President and Chief Executive Officer in June 2014. Mr. Lichtinger served as President, Chief Executive Officer, and a director of Optimer Pharmaceuticals, Inc., from May 2010 to February 2013. Mr. Lichtinger previously served as an executive of Pfizer, Inc. from 1995 to 2009, including as President of Pfizer’s Global Primary Care Unit from 2008 to 2009, Area President, Europe from 2006 to 2008, President, Global Animal Health from 1999 to 2006, and Regional President Europe Animal Health from 1995 to 1999. Before joining Pfizer, Mr. Lichtinger was an executive of Smith Kline Beecham, last serving as Senior Vice-President Europe Animal Health from 1987 to 1995. Mr. Lichtinger serves as a director of BioTime, Inc. and previously served as a director of Optimer Pharmaceuticals, Inc. Mr. Lichtinger holds an MBA degree from the Wharton School of Business and an Engineering degree from the National University of Mexico.

Peter Hoang, Senior Vice President, BD & Strategy, Bellicum Pharmaceuticals, Inc.

Peter Hoang is the Senior Vice President, Business Development & Strategy at Bellicum Pharmaceuticals, where he is head of business development, corporate development and business strategy. He has over 18 years of finance and deal experience in investment banking and venture capital. Prior to Bellicum, he was the Managing Director, Innovations, for The University of Texas MD Anderson Cancer Center where he headed the institution’s new venture formation and development effort.

Prior to MD Anderson, Peter was a senior investment banker, most recently as Managing Director and Head of Healthcare Mergers & Acquisitions advisory for CIT Group, a New York corporate and investment banking firm with over $65 billion in assets (NYSE: CIT). Previously, he also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch and Deutsche Bank. He earned high honors distinction with an M.B.A. from the Anderson School of Management at UCLA and a B.A. from Yale University.

Paul Rennert, Founder & Principal, SugarCone Biotech LLC

I am a top-tier Biotechnology Executive with extensive strategic and leadership experience. I focus on the alignment of R&D, commercial and clinical strategies to drive effective, efficient and successful drug development. My industry expertise covers bench to IND and clinical trial development of biological and small molecule drugs for oncology, autoimmunity, chronic inflammation and fibrosis. Over the past three years I have partnered with investors, diverse companies and academic centers to develop a wide variety of biotechnology companies (deal sheet available). My ability to work so broadly across our industry is based on my long and successful career within biotech, highlighted by multiple successful drug-development campaigns, over 30 patents filed and granted, and more than 80 peer-reviewed publications including recent publications in Nature Reviews Drug Discovery, Immunity, PNAS USA, JCI, and the Journal of Virology.

Current Positions

Co-Founder, President & CSO, Aleta Biotherapeutics Inc. Aleta is developing transformative technologies for use in cellular therapeutics for the treatment of cancer.

Founder & Principal, SugarCone Biotech Consultants LLC. SugarCone Biotech provides C-Suite strategic consulting for the biotech, investment, and pharmaceutical industries.

Co-Founder & Chief Scientific Officer, Videre Biotherapeutics. Videre Biotherapeutics is a targeted-drug-conjugate company with a singular focus on pathways critical for tumor cell survival in protected “niches”.



WELCOM

ESPEAKERS

Speakers

4th ANNUAL



Robert Stein, CSO and Head, R&D, Agenus, Inc.

Dr. Robert Stein, President of R&D, leads our global research and development efforts. Bob, who joined Agenus in January 2014, brings over 35 years of experience and accomplishments in the pharmaceutical and biotech industry to the Agenus leadership team. Over the course of his career Bob has played a significant role in the discovery and development of eight marketed drugs, including Sustiva®, Fablyn®, Viviant®, PanRetin®, TargRetin®, Promacta®, & Eliquis®. Prior to joining Agenus he held a number of progressively responsible senior management positions including Head of Pharmacology for Merck & Co., CSO & SVP of Research for Ligand Pharmaceuticals, EVP of Research & Preclinical Development for Dupont Merck, President and CSO for Incyte Pharmaceuticals, President of Roche Palo Alto, and CEO of KineMed. Bob spent the early part of his career at Merck, Sharp and Dohme Research Laboratories. He holds an MD and a PhD in Physiology & Pharmacology from Duke University.

Robert Urban, Head of the Johnson & Johnson Innovation, Boston, Johnson & Johnson Innovation

Robert leads Johnson & Johnson’s Boston Innovation Center. Johnson & Johnson Innovation Centers are home to investment teams that work closely with entrepreneurs to advance products and technology up to proof-of-concept across the pharmaceuticals, medical device & diagnostic and consumer sectors. Their investments focus on people and programs that have the potential to not just advance healthcare, but to transform it. Located in Boston, Menlo Park, London and Shanghai, the J&J Innovation Centers seek to simplify and expedite the transformation of discoveries into healthcare products that improve lives across the world.

Prior to J&J, Robert was the founding Executive Director of MIT’s Institute for Integrative Cancer Research. Robert has co-founded multiple biopharmaceutical companies, held a variety of R&D leadership/operational roles and served as an advisor or board member in the industry. Robert received his Bachelor of Arts degree in Microbiology and his Ph.D. in Microbiology and Immunology from the University of Texas system and was an Irvington Fellow in structural immunology at Harvard University.

Peter Kolchinsky, Managing Director, RA Capital Management, LLC

Peter Kolchinsky is a founder, Managing Director, and Portfolio Manager at RA Capital Management, a crossover fund manager dedicated to evidence-based investing in healthcare and life science companies. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools, and serves as a member of the Board of Directors of Dicerna Pharmaceutics and a number of private companies. Peter also leads the firm’s outreach and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policy makers, and industry. He authored “The Entrepreneur’s Guide to a Biotech Startup” and served on the Board of Global Science and Technology for the National Academies of Sciences. Peter received a Bachelor’s degree from Cornell University and a PhD in Virology from Harvard University.

Robert Petit, EVP CSO, Advaxis, Inc.

Dr. Robert Petit is the Chief Scientific Officer at Advaxis, Inc. and is responsible for shaping future products and combinations and has personally championed the adaptation of the Advaxis platform toward multiple tumor driver targets as well as personalized neoepitopes. Professionally, he has over 25 years of experience in all medical and scientific aspects of pharmaceutical development. He has led programs in discovery, translational medicine, and clinical development. Robert has designed and conducted U.S. and international clinical evaluation programs for numerous therapies from Translation through clinical Phase 1-4. Dr. Petit joined Advaxis from Bristol-Myers Squibb where he was U.S. Medical Strategy Lead for the ipilimumab program, Director of Medical Strategy for New Oncology Products, and Director of Global Clinical Research. Prior to joining Bristol-Myers Squibb, Robert served as Vice President of Clinical Development at MGI Pharma and also at Aesgen Inc. His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Dr. Petit has significant regulatory filing experience and has contributed to five NDA/BLA filings. Prior to joining industry, Robert co-founded an immune-oncology program affiliated with St. Luke’s and the Medical College of Wisconsin with an appointment in pathology and laboratory medicine. He holds a doctorate from the Ohio State University College of Medicine and a Bachelor of Science from Indiana University.



WELCOM

ESPEAKERS

Speakers

4th ANNUAL



Stuart Barich, Managing Director, Raymond James Financial, Inc.

Stuart has been with Raymond James since February 2015 as a Managing Director focusing on Life Sciences.

Stuart has participated in the successful completion of over 250 transactions during his career, covering a broad spectrum of equity and mergers and acquisitions. Prior to joining Raymond James, Stuart spent almost 10 years at Oppenheimer and five years at Leerink Swann completing numerous transactions for Biotechnology and Specialty Pharmaceutical companies. He previously directed the healthcare banking efforts at Oscar Gruss & Son and Auerbach, after beginning his career as a Corporate Finance Associate with Paine Webber.

Education: BS in Electrical Engineering, University of Rochester; MBA with Honors, Columbia Business School.

Steve Worland, President and CEO, eFFECTOR Therapeutics, Inc.

Steve Worland is President, CEO and a co-founder of eFFECTOR Therapeutics. Previously he was CEO of Anadys Pharmaceuticals, a publicly traded company acquired by Roche in 2011. Dr. Worland blends a background in basic science, product development and business in order to identify and advance opportunities for new therapeutics. Prior to being named CEO at Anadys he served as Chief Scientific Officer and President, Pharmaceuticals. Dr. Worland began his career at Agouron Pharmaceuticals where he was Director, Biochemistry and Molecular Biology and Vice President, Antiviral Research. He received his PhD in Chemistry from the University of Californa, Berkeley and was an NIH Postdoctoral Fellow in Molecular Biology at Harvard University.

Stephen Rubino, Global Head, Business Development and New Products Marketing, Cell & Gene Therapy Unit, Novartis

As Global Head of Business Development and New Product Marketing, Stephen is responsible for building the product pipeline for Novartis’ newly created Cell & Gene Therapies Unit. Stephen has over 20 years of pharmaceutical experience, predominantly in the U.S. and Global commercial, strategy and business development roles. Since joining Novartis in 2001, Stephen has served in a number of different roles which include Head of Investor Relations for North America; Head of Strategic Planning & Business Development for U.S. Gen Meds, where he spearheaded efforts to re-shape the business structure to address changes in the Novartis product pipeline and pharma environment; and Head New Product Commercialization for the U.S .Gen Meds business directing all marketing activities of the pipeline portfolio and BD&L opportunities for products for the Gen Meds portfolio in the therapeutic areas of Neuroscience, Anti-Infective, Joint/Bone, Gastroenterology, CV, Respiratory, and Oncology. Prior to joining Novartis, Stephen spent 10 years at Schering–Plough where his last role was head of the Global Solid Tumor Oncology & Autoimmune Business Unit responsible for the licensing and launch of Remicade, as well as the launch and commercialization of other global brands including Temodal and Caelyx.

In addition, Stephen is published in scientific literature and a holder of U.S .patents. Stephen received a PhD in Microbiology/Virology from Cornell University, Masters in Business Administration and Policy from Baruch College, and a BS in Biology from Muhlenberg College.

Steve Dickman, CEO, CBT Advisors

CBT Advisors Founder-CEO Steve Dickman has worked in the biotechnology and venture capital industries for more than fifteen years. He founded CBT Advisors in 2003 after completing a successful four-year stint as a venture capitalist with TVM Capital in Boston and Munich, where he invested in therapeutics, personalized medicine and life science research tools. His investments included Sirna Therapeutics, which was acquired in 2006 by Merck for $1.1 billion, and bluebird bio (then Genetix Pharmaceuticals), which went public on Nasdaq (BLUE) in 2013 and had a $3 billion valuation in December, 2015. Steve publishes from time to time on Forbes and Boston Biotech Watch.

CBT Advisors works in all areas of life sciences including drug discovery and clinical development, molecular diagnostics, genomics, research tools and bioinformatics and software. A growing area of focus is healthcare information technology (healthcare IT). CBT Advisors pursues projects of four basic types:

• Drafting of prospectus text • Business development • Investor and partner pitches • Market analysis



WELCOM

ESPEAKERS

Speakers

4th ANNUAL



William Kuziel, Senior Director, External Scientific Affairs, Daiichi Sankyo Group

Dr. Kuziel joined Daiichi Sankyo in 2008 and is currently a Director in the External Scientific Affairs group. He is responsible for identifying and evaluating opportunities for research collaboration, in licensing and M&A in the areas of immuno-oncology, cell therapy and advanced technology platforms for the discovery, design and development of novel therapeutic biologics.

Dr. Kuziel received his B.S. in Biology from the Pennsylvania State University and his Ph.D. in Immunology from the University of Texas Southwestern Medical Center at Dallas. He did post-doctoral training in Immunology at the Howard Hughes Medical Institute at the Duke University Medical Center.

After two years as a visiting scientist in the Department of Pathology and Laboratory Medicine at the University of North Carolina Medical Center at Chapel Hill, Dr. Kuziel joined the Department of Molecular Genetics and Microbiology at the University of Texas at Austin as an Assistant Professor. His research focused on making and using novel knockout mouse strains to study the molecular and cellular basis of inflammatory disease processes. He also designed and taught undergraduate courses in Immunology and Infectious Disease.

Dr. Kuziel began his career in drug development in 2004 at Protein Design Labs where he established and led a research group to validate novel therapeutic targets and test monoclonal antibody drug candidates in animal inflammatory disease models. He also served on several therapeutic monoclonal antibody clinical development and life cycle management teams.

Tom Farrell, CEO, Bellicum Pharmaceuticals, Inc.

Tom Farrell has a 17-year track record as a serial life science executive and entrepreneur. He joined Bellicum in February 2006 as CEO, and has built the company into a leader in cellular immunotherapy, with two products in clinical development, a pipeline of novel pre-clinical CAR and TCR product candidates, and more than $300 million in capital raised. Prior to joining Bellicum, he was the founding President and CEO of San Diego based Cylene Pharmaceuticals, a venture-backed company developing a novel class of small molecules as anti-cancer therapy, targeting secondary DNA structures and associated kinases. He received his B.A. in Engineering from the University of Cambridge and his M.B.A. from Stanford Graduate School of Business, where he was an Arjay Miller Scholar.

Thomas Davis, Executive Vice President, CMO, Celldex Therapeutics

Dr. Davis has been involved in clinical cancer immunotherapy in academia, government and industry for over a decade. He trained at Johns Hopkins, Georgetown and Stanford Universities. While at Stanford, Dr. Davis worked with Dr. Ronald Levy, and participated in all phases of clinical development of anti-CD20 antibodies, including rituximab and tositumomab, in both their unlabeled and radiolabeled versions. He also was involved in the translational development of tumor specific idiotype vaccines for the treatment of B-cell malignancies. At the National Cancer he directed the clinical evaluation of a broad assortment of therapeutic monoclonal antibodies targeting human malignancies within the CTEP program and subsequently advanced stage clinical trials in hematologic malignancies and marrow transplantation, coordinating efforts in the NCI funded cooperative groups and consortia. His industry experience includes initiation of clinical development of several antibodies including ipilimumab at Medarex. He is currently Chief Medical Officer at Celldex Therapeutics, Inc, overseeing clinical development of a pipeline of immunotherapies for cancer.



WELCOM

ESPEAKERS

4th ANNUAL



Abzena PLC www.abzena.com

CONTACTJohn Burt Chief Executive Officer

ADDRESS Babraham Research Campus Babraham Cambridge CB22 3AT United Kingdom

TELEPHONE +44 0 1223 903 498

SECTORS

• Biotechnology • Consulting Services • Diagnostics • Drug Delivery • Laboratory Equipment • Medical Devices • Pharmaceuticals/Licensing

COMPANY PROFILE

Abzena provides a suite of complementary services and technologies to R&D organisations to improve the chances of successful development of therapeutic proteins, antibodies and antibody drug conjugates. It is therefore poised to capitalise on the growth of the biopharmaceutical market.

The Group has significant know-how, supported by a broad patent estate, to enable it to create better biopharmaceuticals for its customers.

Abzena operates a balanced business model with growing revenues from its service business and the potential for significant future growth through royalty bearing licences for the application of its technologies to biopharmaceutical products. The Group’s technologies and services are provided through its wholly-owned subsidiaries, PolyTherics, Antitope, PacificGMP and TCRS, The Chemical Research Company.

Abzena group companies have been developing and offering their technologies and services for over 10 years and their scientists have provided expertise to a wide range of companies, including most of the top 20 biopharmaceutical companies, many large and small public and private biotech, and academic groups, across the world.

MANAGEMENT

John Burt, Chief Executive OfficerJulian Smith, Chief Financial OfficerMatthew Baker, Chief Scientific OfficerSally Waterman, Senior VP Corporate DevelopmentCampbell Bunce, Senior VP Scientific OperationsNareshkumar Jain, Senior VP (ADC Biomanufacturing) & Global Head of ChemistryNeil Butt, VP Business DevelopmentJim Mills, VP Technical OperationsDonna Hackett, VP Intellectual Property, Commercial and Legal AffairsLeigh N. Pierce, Chief Technology Officer (Biomanufacturing)Gary Pierce, President, PacificGMP



WELCOM

ESPEAKERS

4th ANNUAL



Advaxis, Inc. www.advaxis.com

CONTACTInvestor Relations/ Business Development Gregory T. Mayes EVP and Chief Operating Officer

ADDRESS 305 College Rd East Princeton, NJ 08540

TELEPHONE +1 609 452 9813

EMAIL [email protected]

SECTORS

• Biotechnology • Not-for-Profit • Pharmaceuticals/Licensing

COMPANY PROFILE

Advaxis is a clinical-stage biotechnology company focused on developing cancer immunotherapies that use the body’s natural immune system to redirect the immune response to kill cancer. For decades, cancer researchers have been trying to stimulate the body’s immune system to identify and kill cancer cells, with the goal of creating a standard “immunologic” treatment against tumors that is more effective and more tolerable than traditional chemotherapy or radiation. Our clinical programs are evaluating the ability of Advaxis cancer immunotherapies to improve survival and reduce the frequency and severity of side-effects commonly associated with standard chemotherapy and radiation.

MANAGEMENT

Daniel J. O’Connor, President and Chief Executive OfficerGreg T. Mayes, EVP and Chief Operating OfficerSara Bonstein, SVP and Chief Financial OfficerRobert Petit, EVP and Chief Scientific OfficerThomas Hare, Vice President, Clinical OperationsRobert Ashworth, Vice President, Regulatory AffairsMayo Pujols, Vice President, Manufacturing



WELCOM

ESPEAKERS

4th ANNUAL



Aethlon Medical, Inc. www.aethlonmedical.com

CONTACTJames A. Joyce Chairman and Chief Executive Officer

ADDRESS 9635 Granite Ridge Drive, Suite 100San Diego, CA 92123 TELEPHONE+1 858-459-7800

YEAR FOUNDED1999

SECTORS

• Medical Devices • Biotechnology

COMPANY PROFILE

The Aethlon Medical mission is to create innovative medical devices and diagnostics that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions.

Our Aethlon ADAPT™ System provides the basis for a new class of therapeutics that target the selective removal of disease-enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians.

Our subsidiary, Exosome Sciences, has proof of concept data for Lectin Affinity Diagnostics which may enable:

Early stage cancer screening tests based on the high-sensitivity capture of tumor-secreted exosomes in blood or urine.

Companion diagnostics based on the analysis of microRNA, proteins and/or other molecules contained in tumor-secreted exosomes captured from a blood or urine sample.

OPPORTUNITIES

Rapid Removal of Tumor Secreted Exosomes from Circulation An understanding is emerging that tumor-secreted exosomes are involved in tumor growth and metastasis and that therefore, abrupt removal of exosomes from the blood stream could immediately impact progression-free survival and overall survival in a variety of cancers.

Aethlon Medical’s Hemopurifier device is a plasmapheresis-like filter cartridge with a proprietary lectin inserted into the extra-luminal space of the cartridge as an affinity agent to capture disease-causing pathogens while the remaining blood and plasma particles return to the patient’s circulation. A Safety Study is currently underway under an approved IDE for investigation in ESRD patients infected with Hepatitis C. The device has been found to capture exosomes from the circulation. A treatment regimen for cancer patients might be similar to that of ESRD patients on dialysis.

This device may also be useful in collection of a large number of a patient’s exosomes for use in an autologous modified-exosome therapy process for the targeted delivery of chemo- or other therapeutics, if developed.

Clinical validation comes from 100 treatment experiences in Hepatitis C, HIV, and Ebola.

Exosome-Based Screening Diagnostics and Companion Diagnostics Validation is emerging that tumor-secreted exosomes may be a robust and dynamic source of biomarkers for early cancer screening tests and companion diagnostics. Exosomes mirror the features of the parent cell and are altered upon infection, transformation or injury. Detection of exosomal components associated with specific pathologies can be utilized as clinically relevant markers. Analyzing multiple exosomal components allows multiplexing to optimize specificity and sensitivity. Exosomes are very stable and make a liquid biopsy possible.

Aethlon Medical and its subsidiary Exosome Sciences discovered that tumor-secreted exosomes bind to lectins and therefore lectins can be an important component in the development of cancer screening tests and companion diagnostics in oncology.

ESI’s diagnostic platform, the Enzyme Linked Lectin Specific Assay (ELLSA), in which lectin affinity has replaced the capture antibody of ELISA, has been shown to detect and quantify the presence of exosomes underlying HIV, TB, and ovarian, bladder, colorectal, lung and pancreatic cancer.

MANAGEMENT

James A. Joyce, Chairman and Chief Executive OfficerMr. Joyce is the founder, Chairman and Chief Executive Officer of Aethlon Medical. Under his leadership, Aethlon has

transformed the concept of a selective therapeutic filtration device (The Aethlon Hemopurifier®) into the reality of treating both

HIV and hepatitis C patients in a clinical setting. Follow-on research has further validated the ability of the Hemopurifier®

Continued...



WELCOM

ESPEAKERS

4th ANNUAL



Aethlon Medical, Inc. www.aethlonmedical.com

CONTACTJames A. Joyce Chairman and Chief Executive Officer

ADDRESS 9635 Granite Ridge Drive, Suite 100San Diego, CA 92123 TELEPHONE+1 858-459-7800

YEAR FOUNDED1999

to capture a broad-spectrum of bioterror and pandemic threats as well as immunosuppressive cancer exosomes. Mr. Joyce

has originated numerous collaborative relationships with government and non-government research organizations, has

authored supporting publications and reports, and raised capital resources to support the mission of Aethlon Medical. He has

represented the Company on CNN, NBC, ABC, and other media outlets and has testified before Congress on issues related

to Project BioShield legislation and the deployment of the Aethlon Hemopurifier® as a countermeasure against biological

weapons. His efforts on Capital Hill were instrumental in expanding the definition of treatment countermeasure in Project

BioShield legislation to include medical devices. In May 2011, the Company introduced the Aethlon ADAPT™ system to

advance Mr. Joyce’s vision of an expansive device platform that converges affinity drug agents with plasma membrane

technology to create new candidate therapies against life-threatening disease conditions. From February 1993 until founding

Aethlon Medical, Mr. Joyce was Chief Executive Officer of James Joyce & Associates. Previously he was founder and Chief

Executive Officer of Mission Labs, Inc., was a principal at London Zurich Securities, Inc., and was a member of the Denver

Broncos Football Club of the National Football League. Mr. Joyce is a graduate of the University of Maryland.

Richard H. Tullis, Ph.D., Senior Vice President, Chief Science OfficerDr. Tullis has extensive biotechnology management and research experience, and is the founder of Syngen Research, a

wholly-owned subsidiary of Aethlon Medical, Inc. Dr. Tullis became a Vice President and Director of Aethlon Medical, Inc. in

January of 2000, and succeeded Dr. Clara M. Ambrus as Chief Scientific Officer in June of 2001. Previously, Dr. Tullis co-

founded Molecular Biosystems, Inc., a former NYSE company. At Molecular Biosystems, Dr. Tullis was Director of Research and

Development, Director of Oligonucleotide Hybridization, Senior Research Scientist and Member of the Board of Directors. In

research, Dr. Tullis developed and patented the first application of oligonucleotides to antisense antibiotics and developed new

methods for the chemical synthesis of DNA via methoxy-phosphorochloridites. Dr. Tullis also co-developed the first applications

of covalently coupled DNA-enzyme conjugates using synthetic oligonucleotides during his tenure at Molecular Biosystems.

In 1985, Dr. Tullis founded, and served as President and CEO of Synthetic Genetics, Inc., a pioneer in custom DNA synthesis,

which was sold to Molecular Biology Resources in 1991. Dr. Tullis also served as interim-CEO of Genetic Vectors, Inc., which

completed its IPO under his management, and was co-founder of DNA Sciences, Inc., a company that was eventually acquired

by Genetic Vectors. Dr Tullis received his Ph.D. in Biochemistry and Cell Biology from the University of California at San Diego,

and has done extensive post-doctoral work at UCSD, USC, and The Scripps Research Institute.

...continued



WELCOM

ESPEAKERS

4th ANNUAL



CONTACTGaro H. Armen, Ph.D. Chairman & CEO

ADDRESS 3 Forbes Road Lexington, MA 02421-7305

TELEPHONE +1 781 674 4400


YEAR FOUNDED1994

FINANCIAL SUMMARY

Agenus has 22 programs in clinical development, between our own pipeline and our strategic partnerships, including three programs currently in Phase 3 clinical trials. Our goal is to build shareholder value by bringing cutting-edge immune-therapies to patients, harnessing the power of the immune system to optimize the treatment of patients with cancer and infectious diseases and to improve the prevention of disease.

COMPANY PROFILE

Agenus is focused in the areas of immuno-oncology and infectious disease. With our strong platform technologies we are advancing multiple product candidates in the clinic and defining the most suitable patient populations that may benefit from our novel therapeutic approaches. Our Retrocyte Display® platform is designed for the rapid screening and high throughput selection of optimized fully human antibodies that have both functional and therapeutic advantages. We have used this platform to develop a range of checkpoint modulators nearing clinical development. Through our heat shock protein platform we are pioneering both autologous and non-autologous candidate vaccines.

MANAGEMENT

Garo H. Armen, Ph.D., Chairman & CEO Evan Ballantyne, Chief Financial Officer Ozer Baysal, Chief Business OfficerJohn Cerio, Vice President, Human Resources & AdministrationChristian Cortis, Ph.D., Vice President, Business Development Alex Duncan, Ph.D, Chief Technology Officer Robert Stein, MD, Ph.D., President, R&DKaren Valentine, JD, Chief Legal Officer & General Counsel

Agenus, Inc. www.agenusbio.com



WELCOM

ESPEAKERS

4th ANNUAL



Asterias Biotherapeutics, Inc. www.asteriasbiotherapeutics.com

CONTACTPedro Lichtinger CEO

ADDRESS 6300 Dumbarton Circle,Fremont, CA 94555USA TELEPHONE+1 510 456 3800

Investor Relations: +1 510 456 3892

[email protected]

YEAR FOUNDED2012

SECTOR

• Biotechnology

COMPANY PROFILE

Asterias Biotherapeutics is a development stage biotechnology company focusing in regenerative medicine. We are developing therapeutics based on two different platform technologies: pluripotent stem cells and dendritic cell cancer immunotherapy. Near term, we are leveraging these platforms to develop treatments to address significant unmet medical needs in neurology and oncology. These mature programs are focused on de-risked indications and are supported by robust proof-of-concept pre-clinical and clinical data.

MANAGEMENT

Pedro Lichtinger, CEOGeorgia Erbez, CFOKaty Spink, COO



WELCOM

ESPEAKERS

4th ANNUAL



Bellicum Pharmaceuticals, Inc. www.bellicum.com

CONTACT Peter Hoang Senior Vice President, Business Development & Strategy

ADDRESS Life Science Plaza 2130 West Holcombe Boulevard, Suite 800 Houston, Texas 77030

TELEPHONE +1 832 384 1100

EMAIL Investor relations: [email protected]

SECTOR

• Biotechnology

COMPANY PROFILE

Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.

MANAGEMENT

Thomas J. Farrell, President and Chief Executive Officer Kevin M. Slawin, M.D., Chief Technology OfficerAnnemarie Moseley, Ph.D., M.D., Chief Operating Officer and Executive Vice President of Clinical DevelopmentAlan A. Musso, CPA, CMA, Chief Financial Officer and TreasurerDavid M. Spencer, Ph.D., Chief Scientific Officer Peter Hoang, Senior Vice President, Business Development & Strategy Ken Moseley, J.D., Senior Vice President and General Counsel Alan K. Smith, Ph.D., Senior Vice President of ManufacturingScott Cullison, Vice President of Commercial Planning and Program Management Martha French, Vice President of Regulatory AffairsAnne Frese, Vice President of Human Resources Joseph Senesac, Vice President of Product DevelopmentSteven Toler, Pharm.D., Ph.D., Vice President of Pharmaceutical Development



WELCOM

ESPEAKERS

4th ANNUAL



BeyondSpring Pharmaceuticals, Inc. www.beyondspringpharma.com

CONTACTRobert Dickey IV, MBA Chief Financial Officer

ADDRESS 28 Liberty Street, 39th Floor New York NY 10005

TELEPHONE +1 (212) 918-4747

YEAR FOUNDED2013

SECTOR

• Biotechnology

COMPANY PROFILE

BeyondSpring Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring is focused on the advancement and commercialization of Plinabulin, a novel, Phase III cancer therapeutic initially targeting non-small-cell lung cancer.

Operationally, BeyondSpring utilizes a unique U.S.-China co-development platform to optimize clinical development speed while reducing costs. The Company has significant experience interacting with the FDA and CFDA. Thus, patient recruitment and clinical trials can be run simultaneously in both geographies, which offers the potential to substantially lower the cost of drug discovery/ development and increase the speed of advancing novel therapies to clinical trials and, ultimately, to the market.

The Company has additional next-generation immuno-oncology assets, as well as a technology platform for targeted drugs and at least 6 new development compounds per year through a recently established 5 year research collaboration with the Fred Hutchinson Cancer Research Center. Led by an expert management team consisting of pharmaceutical industry veterans from the U.S. and China, the Company is well positioned to further advance lead product candidate, Plinabulin, and its other programs.

PRODUCT PIPELINE

Plinabulin: Phase 3 candidate to treat NSCLC Plinabulin, a synthetic analog of a marine microbial product, is an anti-cancer agent that targets and alters the tumor microenvironment. Plinabulin, has begun a Phase III study to treat non-small-cell lung carcinoma (“NSCLC”). This 550-patient clinical trial will be conducted in the United States, China, Australia and New Zealand. Evaluation and enrollment of patients in the U.S. has commenced, with additional sites to be added.

Plinabulin has been evaluated in over 140 patients in the U.S. and select international locations. It has demonstrated promising anti-cancer activity in addition to a favorable safety profile.

Plinabulin works via multiple mechanisms of action to alter the tumor microenvironment such as: 1) acting as an immuno-oncology agent to induce dendritic cell maturation and generate an amplified immune response to the cancer; 2) obliterating existing tumor vasculature via the destruction of tumor vascular endothelium by inhibiting tubulin polymerization, and 3) 2) activating the JNK pathway to induce tumor cell apoptosis.

Plinabulin may be particularly effective against large tumors because of their more abundant tumor vasculature and greater tumor antigen. BeyondSpring is investigating additional clinical programs for Plinabulin in combination with PD-1/PD-L1 inhibitors and for other indications.

MANAGEMENT

Lan Huang, Ph.D., Co-founder, Chairman & CEORamon Mohanlal, M.D., Ph.D., MBA, Chief Medical OfficerRobert Dickey IV, MBA, Chief Financial OfficerG. Kenneth Lloyd, Ph.D., Chief Scientific OfficerWilliam D. Mikrut, MSc., Head of BiostatisticsSteven D. Reich, M.D., Vice President, Clinical AffairsFrederick D. Reno, Ph.D., Head of Nonclinical Safety and ToxicologyGordon L. Schooley, Ph.D., Vice President, Regulatory Affairs



WELCOM

ESPEAKERS

4th ANNUAL



CONTACTJeffrey Bacha Chairman & CEO

ADDRESS Suite 720 - 999 West Broadway Vancouver, British Columbia Canada V5Z 1K5

TELEPHONE +1 604 629 5989


YEAR FOUNDED2010

SECTORS

• Biotechnology • Pharmaceuticals/Licensing

FINANCIAL SUMMARY

• Cash @ September 30, 2015: $2.8 million • Quarterly Burn: ~$1 million • Cash from warrant exercise Q4’2015: ~$400k • Current operating funds into Q3’2016 • Capitalization Dec 31, 2015 (proforma)

Common Shares Outstanding: • DMPI Shares: 40.2 m • ExchangeCo: 4.0 m • Total outstanding: 44.2 m

Warrants: 17.9 m

Options: 3.6 m

Fully Diluted: 65.7 m

COMPANY PROFILE

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company’s lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

PIPELINE

VAL-083 (dianhydrogalactitol) - glioblastoma Refractory (post-Avastin) GBM: Phase II - ongoing trial. Interim data presented SNO-2015. see www.delmarpharma.com Newly Diagnosed GBM in MGMT-unmethylated patients: Phase II planned H1-2016 VAL-083 (dianhydrogalactitol) is a “first-in-class,” small-molecule chemotherapeutic. In more than 40 Phase I and II clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated clinical activity against a range of cancers including lung, brain, cervical, ovarian tumors and leukemia both as a single-agent and in combination with other treatments. VAL-083 is approved in China for the treatment of chronic

DelMar Pharmaceuticals, Inc. www.delmarpharma.com

Continued...

Copyright 2015, DelMar Pharmaceuticals All rights reserved

VAL-083: Building a Pipeline to Address Major Unmet Medical Needs in Oncology

VAL-083 Phase I Phase II Phase III NDA / COMMERCIAL

Lung Cancer – CFDA Approved

Refractory GBM

NSCLC

Potential to expand pipeline in additional indications

CML – CFDA Approved

Front-line GBM

China – Partnered with Manufacturer

Ovarian

Grantsupportedresearch

Pediatric CNS Tumors



WELCOM

ESPEAKERS

4th ANNUAL



CONTACTJeffrey Bacha Chairman & CEO

ADDRESS Suite 720 - 999 West Broadway Vancouver, British Columbia Canada V5Z 1K5

TELEPHONE +1 604 629 5989


YEAR FOUNDED2010

myelogenous leukemia (CML) and lung cancer, and has received orphan drug designation in Europe and the U.S. for the treatment of malignant gliomas.

DelMar has demonstrated that VAL-083’s anti-tumor activity is unaffected by the expression of MGMT, a DNA repair enzyme that is implicated in chemotherapy resistance and poor outcomes in GBM patients following standard front-line treatment with Temodar® (temozolomide).

DelMar recently announced the completion of enrollment in a Phase II clinical trial of VAL-083 in refractory GBM. Patients have been enrolled at five clinical centers in the United States: Mayo Clinic (Rochester, MN); UCSF (San Francisco, CA) and three centers associated with the Sarah Cannon Cancer Research Institute (Nashville, TN, Sarasota, FL and Denver, CO).

In the Phase I dose-escalation portion of the study, VAL-083 was well tolerated at doses up to 40mg/m2 using a regimen of daily x 3 every 21 days. Adverse events were typically mild to moderate; no treatment-related serious adverse events reported at doses up to 40 mg/m2. Dose limiting toxicity (DLT) defined by thrombocytopenia (low platelet counts) was observed in two of six (33%) of patients at 50 mg/m2. Generally, DLT-related symptoms resolved rapidly and spontaneously without concomitant treatment, although one patient who presented with hemorrhoids received a platelet transfusion as a precautionary measure.

Sub-group analysis of data from the Phase I dose-escalation portion of the study suggested a dose-dependent and clinically meaningful survival benefit following treatment with VAL-083 in GBM patients whose tumors had progressed following standard treatment with temozolomide, radiotherapy, bevacizumab and a range of salvage therapies.

Patients in a low dose (≤5mg/m2) sub-group had a median survival of approximately five (5) months versus median survival of approximately nine (9) months for patients in the therapeutic dose (30mg/m2 & 40mg/m2) sub-group following initiation of VAL-083 treatment. DelMar reported increased survival at 6, 9 and 12 months following initiation of treatment with VAL-083 in the therapeutic dose sub-group compared to the low dose sub-group.

VAL-083 (dianhydrogalactitol) - non-small cell lung cancer. Phase II (planned H1 2016) VAL-083 (dianhydrogalactitol) - solid tumors. pre-clinical

OPPORTUNITIES

VAL-083 (dianhydrogalactitol). DelMar Pharmaceuticals is interested in discussing collaborations for development and commercializaiton of VAL-083. The initial indication undergoing clinical development is glioblastoma. Historical clinical data, and DelMar research supports potential utility in a range of solid tumors.

In-licensing DelMar is interested in exploring opportunities to license or acquire small-molecule oncology product candidates in late pre-clinical or early clinical stage development. Interesting product candidates will have first-in-class chemistry and a differentiated mechanism of action.

MANAGEMENT

Jeffrey Bacha, B.Sc., MBA, Chairman & CEO Dennis M. Brown, Ph.D., Chief Scientific Officer Scott Praill, CA, Chief Financial Officer

DelMar Pharmaceuticals, Inc. www.delmarpharma.com

...continued



WELCOM

ESPEAKERS

4th ANNUAL



eFFECTOR Therapeutics, Inc. www.effector.com

CONTACTSteve Worland President & Chief Executive Officer

ADDRESS 11180 Roselle Street Suite A San Diego, CA 92121


SECTOR

• Biotechnology

COMPANY PROFILE

eFFECTOR Therapeutics is a clinical stage company pioneering the discovery and development of translation regulators as a new class of small molecule therapeutics for cancer. The company’s investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTOR’s most advanced program focuses on the development of eFT508, a highly selective MNK1 and MNK2 inhibitor. MNK1 and 2 are kinases that act as signal integrators at the convergence of multiple oncogenic pathways to regulate production of disease-driving proteins. The company has additional translation regulation programs currently in discovery.

MANAGEMENT

Steve Worland, President & Chief Executive Officer Alana McNulty, Chief Financial OfficerSiegfried Reich, Ph.D., Senior Vice President, Research Debra Thoma Vallner, Ph.D., MBA, Vice President, Development Operations Kevin Webster, Ph.D., Senior Vice President, Cancer Biology



WELCOM

ESPEAKERS

4th ANNUAL



F-star Biotechnology Ltd. www.f-star.com

CONTACTJohn Haurum CEO

ADDRESS Schwarzenbergplatz 7, A-1030 Vienna, Austria


YEAR FOUNDED 2006

SECTOR

• Biotechnology

COMPANY PROFILE

F-star designs and develops bispecific antibody products to improve the treatment of cancer. F-star is the only biopharmaceutical company creating bispecific antibodies by modifying the constant region of an antibody. Our Modular Antibody Technology offers unprecedented ease in the development and manufacturing of genuine bispecific antibody products.

F-star’s Modular Antibody Technology allows easy combination of antibody specificities in a “plug-and-play” manner to create unique mAb2 bispecific antibodies and exlpore their novel biology. An Fcab against a single target can be combined with the variable regions of as many different existing antibodies as desired. A mAb2 is full-length antibody which looks like mAb, works like mAb, behaves like mAb and performs beyond mAb.

F-star is developing several products in the immuno-oncology space and has partnerships with AbbVie, BMS, Merck Serono and Boehringer Ingelheim.

PIPELINE

FS102/phase I FS102 is HER2-targeted Fcab, which works differently to current HER2-targeted therapies with the potential to overcome resistance to these drugs. In preclinical studies FS102 showed remarkable efficacy against HER2-positive cancers.

FS102 is currently being tested in phase I clinical trial against breast and gastric cancer through a partnership with Bristol-Myers Squibb.

FS118/preclinical development First-in-class bispecific antibody dual checkpoint inhibitor for the treatment of cancer.

FS118 is designed using F-star’s Modular Antibody Technology, which is ideally suited to produce the next generation of immuno-oncology therapeutics.

Multiple bispecific antibody product candidates in the space of immuno-oncology at discovery stage/

OPPORTUNITY

Out licensing Opportunity Bispecific antibody assets in oncology and immuno-oncology

MANAGEMENT

John Haurum, CEOJane Dancer, CBOTolga Hassan, CFONeil Brewis, CSO



WELCOM

ESPEAKERS

4th ANNUAL



Immune Pharmaceuticals, Inc. www.immunepharmaceuticals.com

CONTACTDaniel Teper Chief Executive Officer

ADDRESS 430 East 29th Street Suite 940 New York 10016 USA

TELEPHONE +1 646 440-9310


SECTORS

• Biotechnology • Pharmaceuticals/Licensing

COMPANY PROFILE

Immune Pharmaceuticals (NASDAQ: IMNP) applies a personalized approach to treating and developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune’s oncology pipeline includes Ceplene®, Azixa® and Crolibulin® as well as bispecific antibodies and nanotherapeutics, including NanomAbs, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. Immune’s lead product candidate, bertilimumab, is in phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan autoimmune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn’s disease, severe asthma and NASH (an inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis. Immune’s non-core pipeline includes AmiKet™, a late clinical stage drug candidate for the treatment of neuropathic pain. Immune is headquartered in the U.S. (Alexandria Center for Life Science, NY), with its primary R&D facilities in Israel.

PIPELINE

Ceplene / Approved in EU and Israel, Ph3 in US Ceplene® (histamine dihydrochloride) is administered in conjunction with low dose interleukin-2 (IL-2), for maintenance of first remission in patients with Acute Myeloid Leukemia (AML). It has been shown in clinical studies to prevent leukemic relapses in AML patients in first remission and prolong leukemia-free survival while maintaining good quality of life during treatment.

AML patients receive intensive induction treatment with chemotherapeutic drugs at diagnosis, and typically become free of detectable leukemia, achieving “complete remission”. However, despite ensuing consolidation therapies, within 1-2 years the majority (75-80%) of adult patients will experience a relapse of leukemia, of which survival prognosis is extremely poor especially in patients over 60 years of age (15-20%). With ~20000 new cases in the US in 2015, poor prognosis following first remission and no other effective remission therapies currently available, AML represents an orphan indication with particularly high unmet need.

Ceplene® acts by enhancing the immunostimulatory effects of IL-2, a T-cell-derived cytokine responsible for activating multiple functions of anti-leukemic T and NK cells. The ability of T and K cells to recognize and eliminate leukemic cells determines the likelihood of maintaining CR in AML. These cells, however, are frequently dysfunctional in AML due to inhibition by myeloid-cell derived reactive oxygen species (ROS). By countering ROS-induced dysfunction and apoptosis of T and NK cells, Ceplene® induces immune-mediated killing of leukemic cells, providing a strong pharmacokinetic rationale for this combination therapy.

A Phase III clinical study of 320 adult patients with acute AML in remission met its primary endpoint of increased leukemia-free survival (p <0.01), indicating that Ceplene® offers an efficacious and tolerable treatment in this population. The absence of treatment-related mortality, combined with the favorable safety profile of Ceplene®, represents a major improvement in the approach to remission maintenance therapy in AML patients. These clinically meaningful, significant results were published in Blood, a leading scientific journal in hematology, (Blood; The Journal of the American Society of Hematology, volume 108, number 1, pp. 88-96, July 1, 2006).

The European Commission has approved Ceplene® for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia in first remission. Ceplene® has been granted orphan drug status for the treatment of AML by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Additional clinical pharmacology and outcomes data in biomarker-defined sub-populations from a post-marketing study conducted in Europe are expected in Q1 2016.

Nanomabs / Preclinical Nanomabs are next-generation immune checkpoint-targeted nanoparticles, which contain thousands of cytotoxic molecules and are conjugated to monoclonal antibodies that recognize antigens in order to enhance the nanoparticles’ specificity, stability and therapeutic efficacy. The nanoparticle comprises of four modules:

Continued...



WELCOM

ESPEAKERS

4th ANNUAL



...continued




TELEPHONE +1 646 440-9310


1. PEGylated polymeric nanoparticles (PPNs) act as a scaffold, which shields the drug from premature elimination or off-target effects.

2. Proprietary linker molecules embedded within the PPN connect the mAb to the rest of the particle.

3. Anti-cancer drug (incorporated within the PEGylated polymeric nanoparticles). Several chemotherapeutic drugs with different mechanism of action have been successfully incorporated as lipophilic prodrugs within NanomAbs, e.g. Paclitaxel, Gemcitabine and Oxaliplatin.

4. Therapeutic mAb mainly functions as a targeting l igand by binding to a specific tumor antigen.

The Nanomabs platform technology may allow highly targeted delivery of chemotherapeutic agents, thereby decreasing the risk of systemic exposure to these products. Nanomabs targeting capabilities include:

A) TUMOR TISSUE TARGETING NanomAbs preferential uptake into tumor tissue based on the enhanced permeability and retention effect

B) TUMOR CELL TARGETING Active targeting to the receptor by mAb leading to active endocytosis of drug loaded NanomAb

C) MOLECULAR TARGETING Intra-cell delivery of chemotherapeutic (s)

Validation of manufacturing processes and preclinical proof of concept with select immune-oncology targets is expected in 2016.

Bispecific Antibody / Preclinical Immune has licensed a novel platform for production of tetravalent IgG1-like bispecific antibodies and patents from Atlante Biotech SAS. Company scientists and collaborators created a prototypic bi-specific antibody that retained effector functions and showed mediation of redirected killing of target HLA-DR+ cells by human CD5+ cytokine-induced killer T-cells, demonstrating direct anti-cancer effects in vitro as well as anti-tumor activity and improved survival in vivo in a mouse xenograft model of disseminated leukemia. Results demonstrated alpha-HLA-DR-CD5 bi-specific antibodies mediate chronic lymphoid leukemia (CLL) cell phagocytosis comparable to rituximab (Rituxan®) with potentially less resistance due to greater specificity. Further research will focus on the application of this novel bispecific platform to target immune checkpoints, and Immune’s plan is to generate additional preclinical data with selected innovative bispecific drug candidates in 2016, particularly in the immuno-oncology space.

OPPORTUNITES

Ceplene Ceplene® (histamine dihydrochloride) is administered in conjunction with low dose interleukin-2 (IL-2), for maintenance of first remission in patients with Acute Myeloid Leukemia (AML). It has been shown in clinical studies to prevent leukemic relapses in AML patients in first remission and prolong leukemia-free survival while maintaining good quality of life during treatment.

AML patients receive intensive induction treatment with chemotherapeutic drugs at diagnosis, and typically become free of detectable leukemia, achieving “complete remission”. However, despite ensuing consolidation therapies, within 1-2 years the majority (75-80%) of adult patients will experience a relapse of leukemia, of which survival prognosis is extremely poor especially in patients over 60 years of age (15-20%). With ~20000 new cases in the US in 2015, poor prognosis following first remission and no other effective remission therapies currently available, AML represents an orphan indication with particularly high unmet need.

Ceplene® acts by enhancing the immunostimulatory effects of IL-2, a T-cell-derived cytokine responsible for activating multiple functions of anti-leukemic T and NK cells. The ability of T and K cells to recognize and eliminate leukemic cells determines the likelihood of maintaining CR in AML. These cells, however, are frequently dysfunctional in AML due to inhibition by myeloid-cell derived reactive oxygen species (ROS). By countering ROS-induced dysfunction and apoptosis of T and NK cells, Ceplene® induces immune-mediated killing of leukemic

continued...



WELCOM

ESPEAKERS

4th ANNUAL



...continued




TELEPHONE +1 646 440-9310


cells, providing a strong pharmacokinetic rationale for this combination therapy.

A Phase III clinical study of 320 adult patients with acute AML in remission met its primary endpoint of increased leukemia-free survival (p <0.01), indicating that Ceplene® offers an efficacious and tolerable treatment in this population. The absence of treatment-related mortality, combined with the favorable safety profile of Ceplene®, represents a major improvement in the approach to remission maintenance therapy in AML patients. These clinically meaningful, significant results were published in Blood, a leading scientific journal in hematology, (Blood; The Journal of the American Society of Hematology, volume 108, number 1, pp. 88-96, July 1, 2006).

The European Commission has approved Ceplene® for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia in first remission. Ceplene® has been granted orphan drug status for the treatment of AML by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Additional clinical pharmacology and outcomes data in biomarker-defined sub-populations from a post-marketing study conducted in Europe are expected in Q1 2016.

Nanomabs Nanomabs are next-generation immune checkpoint-targeted nanoparticles, which contain thousands of cytotoxic molecules and are conjugated to monoclonal antibodies that recognize antigens in order to enhance the nanoparticles’ specificity, stability and therapeutic efficacy. The nanoparticle comprises of four modules:

1. PEGylated polymeric nanoparticles (PPNs) act as a scaffold, which shields the drug from premature elimination or off-target effects.

2. Proprietary linker molecules embedded within the PPN connect the mAb to the rest of the particle.

3. Anti-cancer drug (incorporated within the PEGylated polymeric nanoparticles). Several chemotherapeutic drugs with different mechanism of action have been successfully incorporated as lipophilic prodrugs within NanomAbs, e.g. Paclitaxel, Gemcitabine and Oxaliplatin.

4. Therapeutic mAb mainly functions as a targeting l igand by binding to a specific tumor antigen.

The Nanomabs platform technology may allow highly targeted delivery of chemotherapeutic agents, thereby decreasing the risk of systemic exposure to these products. Nanomabs targeting capabilities include:

A) TUMOR TISSUE TARGETING NanomAbs preferential uptake into tumor tissue based on the enhanced permeability and retention effect

B) TUMOR CELL TARGETING Active targeting to the receptor by mAb leading to active endocytosis of drug loaded NanomAb

C) MOLECULAR TARGETING Intra-cell delivery of chemotherapeutic (s)

Validation of manufacturing processes and preclinical proof of concept with select immune-oncology targets is expected in 2016.

Bispecific Antibody

Immune has licensed a novel platform for production of tetravalent IgG1-like bispecific antibodies and patents from Atlante Biotech SAS. Company scientists and collaborators created a prototypic bi-specific antibody that retained effector functions and showed mediation of redirected killing of target HLA-DR+ cells by human CD5+ cytokine-induced killer T-cells, demonstrating direct anti-cancer effects in vitro as well as anti-tumor activity and improved survival in vivo in a mouse xenograft model of disseminated leukemia. Results demonstrated alpha-HLA-DR-CD5 bi-specific antibodies mediate chronic lymphoid leukemia (CLL) cell phagocytosis comparable to rituximab (Rituxan®) with potentially less resistance due to greater specificity. Further research will focus on the application of this novel bispecific platform to target immune checkpoints, and Immune’s plan is to generate additional preclinical data with selected innovative bispecific drug candidates in 2016, particularly in the immuno-oncology space.

continued...



WELCOM

ESPEAKERS

4th ANNUAL



...continued




TELEPHONE +1 646 440-9310


MANAGEMENT

Daniel Teper, Chief Executive Officer Dr. Miri Ben-Ami, Executive Vice President Oncology, Preseident of Immune Pharma LtdDr. Monica E. Luchi, Executive Vice President Global Drug Development, Chief Medical OfficerG. John Mohr, Senior Vice President of Business Development John Militello, VP Finance Controller, Chief Accounting Officer and Principal Financial Officer



WELCOM

ESPEAKERS

4th ANNUAL



Inovio Pharmaceuticals, Inc. www.inovio.com

CONTACT Niranjan Sardesai, Ph.D. COO

Bernie Hertel VP, Investor Relations

ADDRESS 660 West Germantown Pike Suite 110 Plymouth Meeting, PA 19462

TELEPHONE +1 267 440 4200


SECTOR

• Biotechnology

COMPANY PROFILE

Inovio Pharmaceuticals is a clinical stage company developing DNA based immunotherapies for the prevention and treatment of cancers and infectious diseases. Our DNA plasmid technology allows us to encode for multiple antigens to target heterogeneous tumors. Our immunotherapies can serve as monotherapies that cause cells in the body to produce the encoded antigen(s) to help the immune system recognize the presence of cancer and generate robust CD8 T cells to destroy cancerous cells. Our DNA plasmids can also be used in combination with checkpoint inhibitors or other immuno-oncology products.

PIPELINE (For comprehensive product pipeline please visit: http://inovio.com/products/pipeline)

VGX-3100/ Phase III VGX-3100 is a DNA immunotherapy candidate designed to treat precancers and cancers caused by human papillomavirus (HPV). VGX-3100 includes plasmids targeting the E6 and E7 proteins of HPV types 16 and 18.

INO-5150/Phase I INO-5150 is a dual-antigen DNA immunotherapy targeting prostate-specific membrane antigen and prostate-specific antigen.

MANAGEMENT

J. Joseph Kim, Ph.D., President & CEONiranjan Sardesai, Ph.D., COOMark Bagarazzi, MD, CMOPeter Kies,CFO



WELCOM

ESPEAKERS

4th ANNUAL



CONTACTGerben Moolhuizen Chief Business Development Officer

ADDRESS J.H. Oortweg 19 NL-2333 CH Leiden The Netherlands

TELEPHONE +31 71 33 22 310


SECTOR

• Biotechnology

COMPANY PROFILE

ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology, which have the potential to generate safe and effective immunologic responses with a known mechanism of action. Synthetic long peptides are broadly applicable to multiple targets and ideally suited for monotherapy, as essential components in combination with conventional cancer treatments, and with novel immunomodulators such as Nivolumab. SLP® immunotherapies are designed to fully harness and direct the body’s own defenses towards fighting the disease. In addition, ISA has begun to develop personalized SLP® immunotherapies targeting tumor-specific, mutation-derived neo-antigens. These SLP®s are based on the analysis of specific DNA mutations in a tumor sample, and designed and synthesized for each individual patient.

ISA´s most advanced clinical-stage immunotherapeutic is ISA101, an SLP® immunotherapy targeting human papillomavirus (HPV)-induced diseases. It is currently in clinical development in advanced and recurrent cervical cancer, incurable HPV16-postive solid tumors and anal intraepithelial neoplasia (AIN). Clinical proof-of-concept has been established in vulvar intraepithelial neoplasia (VIN), a pre-cancerous disease caused by HPV.

PIPELINE

OPPORTUNITIES

Investment summary Novel and proprietary immunotherapeutics SLP®platform complimented by proprietary AMPLIVANT® technology

Excellent phase II clinical data / PoC in neoplasias, correlation with immunological responses

Clinical development (ISA101) targeting various HPV-induced diseases

Pre-clinical development in multiple cancers (PRAME) and infectious diseases (e.g. HBV)

SLP®platform being extended for personalized immunotherapies targeting neo-antigens

MANAGEMENT

Ronald Loggers, Chief Executive Officer Cornelis Melief, Ph.D., Chief Scientific OfficerGerben Moolhuizen, Chief Business Development Officer Richard Stead, M.D., Acting Chief Medical Officer

ISA Pharmaceuticals B.V. www.isa-pharma.com



WELCOM

ESPEAKERS

4th ANNUAL



Karus Therapeutics Ltd. www.karustherapeutics.com

CONTACTSimon Kerry Ph.D., MBA Chief Executive Officer

ADDRESS 93 Innovation Drive Milton Park Abingdon Oxfordshire OX14 4RZ

TELEPHONE +44 (0) 1235 829140


YEAR FOUNDED1996

SECTOR

• Biotechnology

FINANCIAL SUMMARY

Karus has raised £29m to date, with the most recent investment froma syndicate of top-tier investors: SV Life Sciences, New Leaf Venture Partners, Novo A/S and IP Group.

COMPANY PROFILE

Karus is a leader in the design and development of innovative small-molecule drugs that combine targeted therapy and immunotherapy activity for the effective treatment of a diverse range of solid and hematological cancers.

PIPELINE

KA2237 – dual inhibitor of PI3K-p110b and p110d. First-in-man studies to start 2Q 2016. Building on an unparalleled knowledge of the PI3K enzyme family’s role in disease pathogenesis, Karus has designed and developed a new class of dual selective inhibitors of PI3K-p110β and p110β. PI3K-p110β is an oncogenic target in its wild-type and mutant forms, and drives cancer cell growth, including in tumors defective in the phosphatase PTEN. PI3K-p110β drives hematological tumor proliferation and survival, and has also emerged as a solid tumor immunotherapeutic target through its role in governing regulatory T cell function. Our orally-active molecules thus have significant therapeutic potential in the treatment of a diverse range of solid and hematological tumors through their combined ability to regulate T cell function and to directly inhibit cancer cell growth and metastasis.

KA2507 – selective HDAC6 inhibitor. In regulatory toxicology studies Drawing on considerable experience in metalloenzyme inhibitor therapeutics, Karus has designed and developed a novel class of highly-selective inhibitors of HDAC6. This enzyme is a unique and functionally distinct member of the HDAC superfamily and is an important emerging drug target in cancer. Inhibition of HDAC6 drives tumor cells into apoptosis by blocking aggresome formation, and also reduces tumor cell-expression of programed death-ligand 1 (PD-L1). Expression of PD-L1 on cancer cells is positively correlated with tumor aggressiveness, and its presence camouflages tumors from attack by immune cells. Our HDAC6-selective inhibitors thus have significant therapeutic potential in solid and hematological tumor therapy through their combined pro-apoptotic and immunotherapeutic activity.

MANAGEMENT Simon Kerry Ph.D., MBA, Chief Executive OfficerProf. Stephen J Shuttleworth Ph.D., FRSC, Chief Scientific OfficerDr Penny Ward, Chief Medical OfficerSimon Jones, Chief Financial Officer



WELCOM

ESPEAKERS

4th ANNUAL



Mirna Therapeutics, Inc. www.mirnatherapeutics.com

CONTACTCasi DeYoung Chief Business Officer

ADDRESS 2150 Woodward St., Suite 100 Austin, TX 78744 USA

TELEPHONE +1 512-901-0900


YEAR FOUNDED2007

SECTORS

• Biotechnology • Consulting Services

COMPANY PROFILE

Mirna is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics and is the first to establish clinical proof-of concept for a microRNA replacement therapy for cancer. Mirna’s lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is currently being studied in a Phase 1 clinical trial in patients with primary liver cancer, advanced solid tumors and hematological malignancies. miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways, with the capacity to regulate more than 30 different oncogenes and repress the immune checkpoint signaling molecule PD-L1. The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs potent anti-cancer agents and less susceptible to drug resistance. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agents. The company was founded in 2007 and is located in Austin, Texas.

MANAGEMENT

Paul Lammers, M.D., M.Sc., President & Chief Executive OfficerMiguel Barbosa, Ph.D., Chief Scientific OfficerSinil Kim, M.D., Vice President Oncology & Chief Medical OfficerCasi DeYoung, M.B.A., Chief Business OfficerAlan Fuhrman, Chief Financial OfficerAndreas Bader, Ph.D., M.S., Vice President Translational Research & DevelopmentDavid Brown, Ph.D., Vice President Preclinical PharmacologyJon Irvin, Vice President FinanceNeil Leatherbury, M.S., Director, Pharmaceutical DevelopmentJay Stoudemire, Ph.D., Vice President Preclinical Development, Regulatory & Quality Assurance



WELCOM

ESPEAKERS

4th ANNUAL



OncoSec Medical, Inc. www.oncosec.com

CONTACTPunit Dhillon President and CEO

ADDRESS 5820 Nancy Ridge Drive, San Diego, CA 92121

TELEPHONE +1 855 662 6732


YEAR FOUNDED2011

SECTOR

• Biotechnology

COMPANY PROFILE

OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec’s core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse™ have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec’s lead program evaluating ImmunoPulse™ for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse™ in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

PRODUCT PIPLINE

ImmunoPulse IL-12 - Phase 2 clinical trials ImmunoPulse™ is designed to enhance local delivery and uptake of DNA-based therapeutics directly into tumors. Clinical studies of ImmunoPulse™ with DNA-based IL-12 demonstrated the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. This technology employs electroporation, which involves the use of electrical pulses to increase the permeability of the cell membrane, permitting the DNA to enter the cells.

OPPORTUNITY

ImmunoPulse ImmunoPulse™ is designed to enhance local delivery and uptake of DNA-based therapeutics directly into tumors.

MANAGEMENT

Punit Dhillon, President and CEORichard B. Slansky, Chief Financial OfficerRobert H. Pierce, M.D., Chief Scientific OfficerSheela Mohan-Peterson, Chief Legal and Compliance Officer



WELCOM

ESPEAKERS

4th ANNUAL



CONTACTSDr. Mike Khan Chief Medical Officer

Dr. Lucio Iannone Research & Business Development Manager

ADDRESS 72 Hammersmith Road London W14 8TH

TELEPHONE +44 (0)203 457 6900


YEAR FOUNDED2007

SECTOR

• Biotechnology

COMPANY PROFILE

We are a drug development company with a proprietary genetic medicine platform.

Our technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo. We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet clinical need. Silence’s technology is currently in the clinic in a Phase 2a pancreatic cancer trial.

MANAGEMENT

Ali Mortazavi, Chief ExecutiveTimothy Freeborn, Chief Financial Officer Dr. Mike Khan, Chief Medical Officer Dr. Lars Karlsson, Head of Research and DevelopmentDr. Jörg Kaufmann, Chief Scientific Officer

Silence Therapeutics www.silence-therapeutics.com



WELCOM

ESPEAKERS

4th ANNUAL



Vaccinex, Inc. www.vaccinex.com

CONTACTDr. Maurice Zauderer Founder, President & CEO

ADDRESS 1895 Mount Hope Avenue, Rochester, NY 14620

TELEPHONE +1 585-271-2700


SECTOR

• Biotechnology

COMPANY PROFILE

Oncology - Vaccinex has discovered and developed an immune-modulating, anti-semaphorin 4D (SEMA4D) antibody that has been shown in preclinical studies to regulate the infiltration of immune cells into the tumor microenvironement. Specifically, anti-SEMA4D induces an increase in tumor-specific cytotoxic T cells and a change in the balance of tumoricidal and regulatory macrophage toward a pro-inflammatory, anti-tumorigenic response. Phase 2 trials are being planned

Neurology - Vaccinex is investigating the ability to protect neurons from degeneration and to effectively prevent or delay the onset of Huntington’s Disease (HD) by blocking the inflammatory response of astrocytes and microglia as mediated by SEMA4D. In HD, it is thought that chronic activation of astrocytes and microglia, the natural inflammatory cells of the brain, may contribute importantly to the degenerative process in this and other neurological disorders. A phase 2 trial is ongoing.

Drug Discovery - Vaccinex has developed a proprietary platform called ActivMAb to enable the efficient identification of high-affinity, full-length human monoclonal antibodies with built-in manufacturability and favorable biophysical properties ideally suited for downstream development. We took the throughput and flexibility of phage and yeast display and migrated it to mammalian cells. We have used this platform for the discovery and development of human therapeutic monoclonal antibodies to treat serious diseases with unmet needs for internal and external projects.

PRODUCT PIPLINE

MANAGEMENT

Dr. Maurice Zauderer, Founder, President & CEO Steven P. Cobourn, C.P.A., Chief Financial Officer Raymond E. Watkins, Senior Vice President and Chief Operating OfficerJohn E. Leonard, Ph.D., Senior Vice President, DevelopmentErnest S. Smith, Ph.D., Senior Vice President, Research and Chief Scientific Officer



WELCOM

ESPEAKERS

4th ANNUAL



CONTACT John Simard CEO

ADDRESS 8201 E Riverside Dr. Bldg 4 STE. 100, Austin, Texas 78744

TELEPHONE +1 512 386 2900 1


YEAR FOUNDED 2006

SECTOR

• Biotechnology

COMPANY PROFILE

XBiotech is a leading developer of True Human™ antibody therapy for various indications such as oncology, inflammation and infectious diseases. We have three programs that have been Fast Tracked by the FDA - our lead molecule Xilonix for colorectal cancer in Phase 3, MABp1 for cardiovascular diseases in Phase 2 and finally our 514G3 molecule for S. aureus in Phase 1/2. Our approach, isolating human antibodies from healthy volunteers, assures us a safer approach to treatment.

PRODUCT PIPELINE

Xilonix for Colorectal cancer. Completed Phase 3 under guidance from the EMA where it met all its end points. Global Phase 3 designated Fast Track by FDA for which patient enrollment is ongoing. Xilonix™ is a first-in-class True Human™ monoclonal (IgG1k) antibody that neutralizes biological activity of interleukin-1a. Specific antagonism of IL-1a through Xilonix™ therapy is viewed as a unique, broad acting tumor suppression strategy that encompasses significant activity to ameliorate symptoms associated with the disease. IL-1a is unique in its involvement in so many processes related to tumor progression and collateral symptomatic effects of malignancy. The excellent safety and tolerability profile of the agent make it an ideal treatment option in advanced stage disease, particularly where the use of cytotoxic or other therapies with considerable toxicity are not supported by cost benefit analysis.

MABp1 for for cardiovascular diseases. Phase 2 completed. XBiotech recently completed a groundbreaking clinical study in cardiovascular medicine. This Phase II randomized, multi-center clinical study evaluated a True Human™ therapeutic antibody MABp1 for its ability to reduce adverse events after balloon angioplasty, atherectomy or stent placement in patients undergoing revascularization procedures for blockage of a major artery (superficial femoral artery or SFA) in the leg. Interim data from this study was submitted to the FDA and resulted in Fast Track designation for this drug development program.

514G3 for S. aureus. Phase 1/2 ongoing 514G3 was screened from the blood of hundreds of healthy individuals and specifically targets the S. aureus mechanism crucial for its immune evasion strategies. 514G3 is not just specific against S. aureus evasion machinery, but also highly resistant to manipulation from the organism. Early clinical results show great promise in the opsonizationof the bacteria.

XBiotech USA, Inc. www.xbiotech.com

continued...



WELCOM

ESPEAKERS

4th ANNUAL



CONTACT John Simard CEO

ADDRESS 8201 E Riverside Dr. Bldg 4 STE. 100, Austin, Texas 78744

TELEPHONE +1 512 386 2900 1


YEAR FOUNDED 2006

OPPORTUNITIES

Oncology program We have two ongoing programs - mono therapy against colorectal cancer and a Phase 2 combination therapy with Tarceva against NSCLC. We beleive, and results demonstrate, that our unique, broad acting tumor suppression strategy encompasses significant activity to ameliorate symptoms associated with the disease. The excellent safety and tolerability profile of the agent make it an ideal treatment option in advanced stage disease, particularly where the use of cytotoxic or other therapies with considerable toxicity are not supported by cost benefit analysis.

MABp1 and inflammation program Using MABp1 antibody to inhibit white blood cell infiltration of the artery may be broadly beneficial to vascular health. In particular, using such an antibody therapy after angioplasty procedure may reduce subsequent arterial inflammation and provide a means to reduce the incidence or severity of restenosis.

Clinical results to date using MABp1 antibody therapy have shown important reduction in the occurrence of restenosis, and reduced incidence of MACE in treated patients compared to controls. These data, together with the FDA Fast Track designation, have supported advancement of the clinical trial program for the treatment of vascular injury and disease.

514G3 and infectious disease program Using XBiotechs Super High Stringency Antibody Mining technology (SHSAM™). SHSAM™ has enabled us to identify clinically relevant antibodies-discovered from literally trillions of irrelevant background antibody molecules in the blood of healthy donors. We have repeatedly demonstrated our ability to discover, develop and take to the clinic in months, molecules against S. auerus, Ebola and C. difficlles. Our 514G3 is not only safe and highly tolerated, it also is able to neutralize the immune evasion mechanism of the bacteria while opsonizing it.

We can use our SHSAM approach against any infectious disease target.

MANAGEMENT

John Simard, CEOQueena Han, VP FinanceSushma Shivaswamy, Ph.D., VP, R&D.Kalidip Choudhury, Ph.D., VP, Business DevelopmentMichael Stecker, M.D., Medical Director.Kelly Thornburg, Sr. VP. Operations

XBiotech USA, Inc. www.xbiotech.com

...continued



WELCOM

ESPEAKERS


Silver Sponsor

4th ANNUAL


www.bellicum.com

Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.

Our lead product candidate, BPX-501, is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation, and is currently being evaluated in multiple Phase 2 clinical trials.

We are also focused on developing more effective, controllable next-generation chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies. Our next-generation adoptive cell therapies incorporate our novel and proprietary technologies, including our Chemical Induction of Dimerization (“CID”) based molecular switches and our MyD88/CD40 (“MC”) based dual co-stimulatory domain, enabling us to more effectively control the behavior of our cell therapies in patients.

We are advancing several product candidates into human clinical trials, including BPX-401, a CAR T product candidate for hematological cancers that express the CD19 antigen; BPX-601, a CAR T product candidate for solid tumors overexpressing the prostate stem cell antigen, or PSCA; and BPX-701, a TCR product candidate for solid tumors expressing the preferentially-expressed antigen in melanoma, or PRAME.

Bellicum Pharmaceuticals, Inc.



WELCOM

ESPEAKERS

t back :: next u


Supporters

4th ANNUAL


www.biodeutschland.org

As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences.

The Berlin-based association currently has over 300 members. It is run by a board of ten members consisting of CEOs and managing directors of biotechnology companies, as well as directors of BioRegions. This committee comprehensively represents the various fields in the sector.

The member companies and their experts are organised in working groups that deal with the following topics: finance and taxation; licences and technical contracts; regulatory matters; innovation and entrepreneurship; HR; German-US cooperation; health policy; competition and regulatory policy; technology transfer; and PR. Using a wide range of political initiatives, BIO Deutschland lobbies for improvements to the legal parameters for innovative small and medium-sized enterprises.

BIO Deutschland is Germany’s biotechnology sector representative at the European association, EuropaBio, in Brussels. BIO Deutschland also works closely with other biotech organisations in Europe and the USA in order to lobby for the interests of the sector in an internationally coordinated way. The association is also very active in a broad range of events with the aim of providing biotechnology with a platform for discussion and interaction.

BIO Deutschland



WELCOM

ESPEAKERS

t back :: next u


Supporters

4th ANNUAL


www.biotechgate.com

Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries.

There are currently over 36,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.

Biotechgate



WELCOM

ESPEAKERS

t back :: next u


Supporters

4th ANNUAL


www.citigatedr.co.uk

Citigate Dewe Rogerson is one of the world’s leading strategic communications consultancies.

Our Life Sciences team has established a reputation for excellence spanning financial, corporate and scientific communications; this has enabled us to become trusted advisors and to build a broad portfolio including some of the most innovative and exciting international life sciences companies. Our clients are at all stages of development, from start-up to multinationals, and our activities are focused on delivering campaigns that support corporate objectives. As a result, we have been involved in major corporate transactions and events in the life sciences sector over the past decade such as IPOs, other public and private fundraisings, and M&As.

Recent IPO transactions: ABIVAX (Euronext Paris - €60m), OSE Pharma (Euronext Paris - €21m), Nordic Nanovector (Oslo – NOK575m), Midatech Pharma (London AIM - £32m), Abzena (London AIM - £20m), arGEN-X (Brussels - €42m), Pixium Vision (Euronext Paris - €39.5m), Crossject (Euronext Paris - €17m). Other recent financings: Abingworth (£225m ABV VI), Rigontec (€14.25m Series A), Calcivis (£4.5m fundraising), ViraTherapeutics ($3.6m - Series A). Recent M&A: Heptares (up to $400m acquisition by Sosei), Prosonix (up to £100m acquisition by Circassia), bioquell (Sale of subsidiary for £44.5m).

Citigate Dewe Rogerson



WELCOM

ESPEAKERS

t back :: next u


Supporters

4th ANNUAL


www.edisongroup.com

Edison is an international advisory firm with around 450 corporate clients and 110 people working from offices in London, New York, Frankfurt, Sydney and Wellington.

The team consists of 80 analysts, investment and logistics professionals with experience in capital markets, investor roadshows and communications. Healthcare is Edison’s largest sector, with 16 analysts covering over 100 biotech and medtech stocks across the UK, continental Europe, North America and Asia-Pacific.

Edison



WELCOM

ESPEAKERS

t back :: next u


Supporters

4th ANNUAL


FreeMind www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources.

Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date. Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen.

FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist our clients in making non-dilutive funding a key tool in their long-term financial strategy.



WELCOM

ESPEAKERS

t back :: next u


Supporters

4th ANNUAL


www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy.

With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities.

Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our headquarters in London, and bases across Europe, AsiaPac and the USA.

Instinctif Partners



WELCOM

ESPEAKERS

t back :: next u


Supporters

4th ANNUAL


www.onenucleus.com

One Nucleus is an international membership organisation for life science and healthcare companies. We are based in Cambridge with the majority of our members across the Cambridge/London corridor – at the heart of Europe’s largest life science and healthcare cluster.

Organisation History: Established in 1997, One Nucleus is a not-for-profit membership organisation located in Cambridge. We have over 470 organisations as members, including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

One Nucleus’ mission is to maximise the global competitiveness of our members. For our science and technology-based members, that means them being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For our business and professional services members, it means them delivering exceptional services that significantly enhance the business performance of their clients.

One Nucleus



WELCOM

ESPEAKERS

t back :: next u


Supporters

4th ANNUAL


Swiss Biotech www.swissbiotech.org

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area).

The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services. The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry.

The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.



WELCOM

ESPEAKERS


Supporters

4th ANNUAL


www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics.

We work with both public and private emerging growth companies:

1. To enhance valuation

2. To build visibility for partnerships and strategic alliances

Tiberend Strategic Advisors, Inc.

Sachs Associates Ltd is a London-based company, which organises and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

The benefits of conference participation with Sachs Associates may be summarised as follows:

Multimedia ExposureSachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out through video streaming and extensive events coverage through major international financial news agencies,including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long establishedrelationships with other financial press organisations globally, which allow further effective distribution onbehalf of its clients.

Eminent SpeakersSachs Associates is committed to ensuring that its events continue to provide forums with the participation ofthe most eminent speakers from the public and private sectors. Through its reputation and its long-establishedlocal relationships, the Company has attracted very senior political and economic personalities as speakersat its events.

Sponsorship and Marketing Opportunities for forthcoming eventsSachs Associates has developed an extensive knowledge of the key individuals operating within the Europeanand global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at theforefront of the industry and provides a powerful tool by which to increase the position of your company in thismarket.

Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients.All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most outof attending our industry driven events.

The following sponsorship and marketing opportunities are available at future conferences:• Conference Sponsor – including workshops and social events• Exhibition stands• Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities please callSilvia Kar on +44 203 463 4890.



WELCOM

ESPEAKERS

Organisers

4th ANNUAL



Sachs Associates www.sachsforum.comwww.sachsforum.comSachs Associates



WELCOM

ESPEAKERS

www.sachsforum.com

4T

H A

NN

UA

L C

AN

CE

R B

IOP

AR

TN

ER

ING

& I

NV

ES

TM

EN

T F

OR

UM

27 Belsize LaneLondon NW3 5AS

Tel: +44 (0)203 463 4890Fax: +44 (0)207 691 7919

Follow us on Twitter – @SachsAssociates

We look forward to seeing you at:

9th Annual European Life Science CEO Forum & Exhibition Partnering & Investing In Biotech & Pharma Industry15th – 16th March 2016 • Hilton Zurich Airport Hotel • Switzerland

2nd Annual Immuno-Oncology: BD&L and Investment Forum

3rd June 2016 • Hyatt Chicago Magnificent Mile • USA

4th Annual MedTech & Digital Health Forum

For Technology & Healthcare Innovation26th September 2016 • Congress Center Basel • Switzerland

16th Annual Biotech in Europe Forum

For Global Partnering & Investment27th – 28th September 2016 • Congress Center Basel • Switzerland

For more information about all our events please visit www.sachsforum.com

speakers 4th annual cancer biopartnering & investment · pdf file ·...

Documents